Page last updated: 2024-11-12

oxadiazoles

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10523409
CHEMBL ID2270334
MeSH IDM0015620

Synonyms (5)

Synonym
nsc726622
nsc-726622
oxadiazoles
CHEMBL2270334
2-[(4-chlorophenoxy)methyl]-5-(2,4-dichloro-5-fluorophenyl)-1,3,4-oxadiazole

Research Excerpts

Overview

Oxadiazoles are a class of antibacterials discovered by in silico docking and scoring of compounds against the X-ray structure of a penicillin-binding protein.

ExcerptReferenceRelevance
"Oxadiazoles are a class of heterocycle containing one oxygen and two nitrogen atoms, available in three isomeric forms."( Furazans in Medicinal Chemistry.
Barden, CJ; Mancini, RS; Reed, MA; Weaver, DF, 2021
)
1.34
"The oxadiazoles are a class of antibacterials discovered by in silico docking and scoring of compounds against the X-ray structure of a penicillin-binding protein. "( The oxadiazole antibacterials.
Chang, M; Janardhanan, J; Mobashery, S, 2016
)
0.99

Effects

Oxadiazoles have been used frequently in drug-like molecules as bioisosteres for ester and amide functionalities. Oxadiazole have been reported to have effect on vascular smooth muscles and calcium influx.

ExcerptReferenceRelevance
"Oxadiazoles have been used frequently in drug-like molecules as bioisosteres for ester and amide functionalities and displayed numerous prominent pharmacological effects. "( Substituted oxadiazoles: a patent review (2010 - 2012).
Hajimahdi, Z; Zarghi, A, 2013
)
2.21
"Oxadiazoles have been reported to have effect on vascular smooth muscles and calcium influx."( Vasorelaxant effect in rat aortic rings through calcium channel blockage: a preliminary in vitro assessment of a 1,3,4-oxadiazole derivative.
Bankar, GR; Chamallamudi, MR; Nampurath, GK; Nandakumar, K; Nayak, PG; Thakur, A, 2009
)
1.07
"Oxadiazoles have been observed to exhibit antiviral activities against RNA viruses."( Synthesis and the biological evaluation of 2-benzenesulfonylalkyl-5-substituted-sulfanyl-[1,3,4]-oxadiazoles as potential anti-hepatitis B virus agents.
Ang, TH; Bai, J; Chen, Y; Kong, KH; Lam, Y; Li, Y; Lim, SG; Tan, TM, 2006
)
1.27

Toxicity

ExcerptReferenceRelevance
" The toxic potencies of glutamate, quisqualate, and homocysteate were inversely proportional to the concentration of cystine in the medium, suggesting that they competitively inhibit cystine uptake."( Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake.
Coyle, JT; Murphy, TH; Schnaar, RL, 1990
)
0.28
" When present during the exposure, 6-cyano-2,3-dihydroxy-7-nitroquinoxaline (CNQX, 10 microM), an antagonist with preferential action on non-N-methyl-D-aspartate receptors, did not prevent this toxic effect of QA."( Quisqualate neurotoxicity: a delayed, CNQX-sensitive process triggered by a CNQX-insensitive mechanism in young rat hippocampal slices.
Garthwaite, G; Garthwaite, J, 1989
)
0.28
"It has long been proposed that the excitatory and toxic properties of acidic amino acid receptor agonists are linked."( Amino acid neurotoxicity: relationship to neuronal depolarization in rat cerebellar slices.
Garthwaite, G; Garthwaite, J; Hajós, F, 1986
)
0.27
" Investigational toxicology methods, using appropriate models and hypotheses, can often resolve problems, identify toxic chemical substituents and salvage therapeutic discovery programs."( Cultured hepatocytes as investigational models for hepatic toxicity: practical applications in drug discovery and development.
Bacon, JA; Cramer, CT; Peng, GW; Petrella, DK; Stryd, RP; Sun, EL; Ulrich, RG, 1995
)
0.29
"The results presented in this study indicate that the toxic response brought about by increasing concentrations of tert-butylhydroperoxide in CHP100 cells was mitigated significantly by exogenously added nitric oxide donors via a cyclic GMP-independent mechanism."( Different signalling pathways mediate the opposite effects of endogenous versus exogenous nitric oxide on hydroperoxide toxicity in CHP100 neuroblastoma cells.
Cantoni, O; Clementi, E; Guidarelli, A; Sciorati, C, 1999
)
0.3
" Furthermore, while the toxic effect of NOR3 was attenuated by replacing the medium at 20 min, 1 or 2 h after drug addition, it was continued by replacing the medium at 3 h or later after drug addition."( Kinetic characterization of the nitric oxide toxicity for PC12 cells: effect of half-life time of NO release.
Kato, T; Nakamura, K; Yamamoto, H; Yamamoto, T; Yuyama, K, 2000
)
0.31
" Idiosyncratic toxic responses are often not detected during this phase in development due to their relative rarity in incidence and differences in species sensitivity."( Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon.
Bacon, JA; Brass, EP; Cramer, CT; Petrella, DK; Sun, EL; Ulrich, RG, 2001
)
0.31
" To determine whether this benefit can be extended beyond neuropathic pain, the present study examined the analgesic activity and adverse effect profile of co-administered NS-9283 and ABT-594 in a variety of preclinical models in rats."( Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.
Baker, S; Brown, J; Chandran, P; Chin, CL; Decker, MW; Fox, GB; Gauvin, D; Gomez, E; Gopalakrishnan, M; Honore, P; Jacobson, PB; Komater, V; Lee, CH; Lewis, LG; Mikusa, J; Pai, M; Rustay, NR; Salyers, A; Simler, G; Tovcimak, A; Zhong, C; Zhu, CZ, 2011
)
0.37
"The trial demonstrates that proxodolol is highly effective and safe in the treatment of AH."( [Efficacy and safety of the first made in Russia αβ long-acting adrenoblocker proxodolol in patients with arterial hypertension of the second degree].
Beliaeva, SA, 2011
)
0.37
"Proxodolol is effective and safe in hypertension, in a dose 120 mg its activity is the same as carvedilol in a dose 25 mg."( [Efficacy and safety of the first made in Russia αβ long-acting adrenoblocker proxodolol in patients with arterial hypertension of the second degree].
Beliaeva, SA, 2011
)
0.37
" Adverse events were generally mild, occurring more frequently in elderly subjects, with no observed difference between subjects receiving avagacestat and placebo."( A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
Albright, CF; Berman, RM; Castaneda, L; Croop, R; Dockens, R; Gu, H; Huang, SP; Li, H; Slemmon, R; Smith, C; Sverdlov, O; Tong, G; Wang, JS; Wong, O, 2013
)
0.39
" Treatment-emergent serious adverse events were similar across placebo and treatment groups."( Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Albright, C; Andreasen, N; Andreasson, U; Berman, RM; Blennow, K; Brody, M; Colby, S; Coric, V; Dockens, R; Feldman, HH; Pachai, C; Pilcher, G; Portelius, E; Richter, RW; Rollin, L; Salloway, S; Shiovitz, T; Soares, H; Soininen, H; Thein, S; van Dyck, CH, 2012
)
0.38
" To study the potential for adverse effects and particularly neurotoxicity, brain histopathological exams were performed in rats treated for 4 days with 5PAM523 or vehicle."( Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
Anthony, NJ; Fauré, H; Forest, T; Gomez, R; Hargreaves, R; Huszar, SL; Hutson, PH; Lambeng, N; Le Poul, E; Magliaro, BC; Mattson, BA; Menzel, K; O'Brien, JA; Parmentier-Batteur, S; Poli, S; Rocher, JP; Rosahl, TW; Stump, CA; Tucker, TJ; Tynebor, RM; Uslaner, JM; Williams, TM; Zhang, XF, 2014
)
0.4
"To study the 3, 4- dinitro-furazan-based oxidation furazan (DNTF) of sub-acute toxicity and chronic toxicity, to determine the acute toxicity classification DNTF, the nature of toxic effects and major target organ for the development provide the basis for occupational exposure limits."( [3, 4- dinitro-furazan-based oxidation furazan acute and subchronic toxicity studies].
Du, WX; Sun, YH; Wang, YL; Xie, F; Xing, YF; Zhang, YW, 2013
)
0.39
"( 1) Acute oral toxicity test results indicate that DNTF rat oral LD50 greater than 5000 mg/kg, DNTF mice treated by oral LD50 4589 mg/kg, 95%confidence limit for the 4026-5230 mg/kg, Acute toxicity grade level is low toxicity compounds."( [3, 4- dinitro-furazan-based oxidation furazan acute and subchronic toxicity studies].
Du, WX; Sun, YH; Wang, YL; Xie, F; Xing, YF; Zhang, YW, 2013
)
0.39
" Treatment with 10-mg azilsartan was similar to 8-mg candesartan cilexetil in its association with rare adverse events."( Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial.
Arai, A; Kaneto, H; Katakami, N; Kusuda, Y; Matsuoka, TA; Shimomura, I; Shindo, M; Shiraiwa, T; Takahara, M, 2014
)
0.4
" We also demonstrate that GSK356278 enhances performance in a model of executive function in cynomolgus macaques with no adverse effects, a therapeutic profile that supports further evaluation of GSK356278 in a clinical setting."( GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
Arban, R; Cavallini, P; Davies, CH; Davis, TG; Gray, FA; Montanari, D; Negri, M; Poffe, A; Rutter, AR; Schneck, J; Vicentini, E; Wren, PB, 2014
)
0.4
" The most common adverse events, irrespective of treatment, were dizziness (8."( Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension.
Barger, B; Handley, A; Kipnes, MS; Lloyd, E; Roberts, A, 2015
)
0.42
" The frequency of adverse events was similar for AZL-M (32%) and placebo (29%)."( Effects of Age, Sex, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of Azilsartan Medoxomil in Healthy Subjects.
Dudkowski, C; Harrell, RE; Karim, A; Zhang, W, 2016
)
0.43
" Adverse events were mild in intensity, apart from one moderate event (migraine)."( Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults.
Dudkowski, C; Juhasz, A; Tsai, M; Webb, NJ; Wells, T; Zhao, Z, 2016
)
0.43
"This dosing strategy should be safe in pediatric patients, as AZL exposure would not exceed that seen in adults with the highest approved AZL-M dose (80 mg)."( Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults.
Dudkowski, C; Juhasz, A; Tsai, M; Webb, NJ; Wells, T; Zhao, Z, 2016
)
0.43
" Adverse events (AEs) were reported in 75."( Safety and tolerability of azilsartan medoxomil in subjects with essential hypertension: a one-year, phase 3, open-label study.
Barger, B; Handley, A; Lloyd, E; Roberts, A, 2016
)
0.43
" Three serious adverse events unrelated to treatment were reported in patients assigned ozanimod 0·5 mg: optic neuritis, somatoform autonomic dysfunction, and cervical squamous metaplasia (HPV-related)."( Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
Arnold, DL; Bar-Or, A; Cohen, JA; Comi, G; Cravets, M; Frohna, PA; Gujrathi, S; Hartung, JP; Olson, A; Selmaj, KW, 2016
)
0.43
" SD of up to 24 mg and RD of up to 6 mg/day for 28 days were reasonably tolerated, despite higher incidences of gastrointestinal and cardiovascular adverse events compared to placebo."( Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers.
Gray, F; Henderson, A; Hicks, K; Oliver, J; Thompson, P; Xu, J; Yang, J, 2014
)
0.4
" Treatment-emergent adverse events/serious adverse events occurred in 78."( Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide.
Barger, B; Cushman, WC; Handley, A; Lloyd, E; Neutel, JM, 2017
)
0.46
"Most adverse events (AEs) were mild or moderate in intensity, and no deaths or treatment-related serious AEs were reported."( A phase III, open-label, multicenter study to evaluate the safety and efficacy of long-term triple combination therapy with azilsartan, amlodipine, and hydrochlorothiazide in patients with essential hypertension.
Nishiyama, Y; Rakugi, H; Sano, Y; Shimizu, K; Umeda, Y, 2018
)
0.48
" There were no significant treatment-emergent adverse events leading to discontinuation during the study."( Efficacy and safety of the G protein-coupled receptor 119 agonist DS-8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo-controlled study.
Nakatsuka, Y; Shiosakai, K; Taguchi, T; Terauchi, Y; Washio, T; Watada, H; Yamada, Y, 2018
)
0.48
"Exposure to herbicides can induce long-term chronic adverse effects such as respiratory diseases, malignancies and neurodegenerative diseases."( Oxadiazon affects the expression and activity of aldehyde dehydrogenase and acylphosphatase in human striatal precursor cells: A possible role in neurotoxicity.
Barletta, E; Chevanne, M; Degl'Innocenti, D; Monti, D; Ramazzotti, M; Sarchielli, E; Vannelli, GB, 2019
)
0.51
" Dual mTORC1/mTORC2 inhibitor AZD2014 showed no considerable effects on embryonic cells of zebrafish in concentrations substantially toxic in cancer cells."( Comparative toxicity evaluation of targeted anticancer therapeutics in embryonic zebrafish and sea urchin models.
Babic, T; Buric, SS; Dinic, J; Hadzic, S; Pesic, M; Radojkovic, D; Rankov, AD, 2018
)
0.48
" Few ozanimod-treated participants discontinued treatment because of adverse events (13 [2·9%] who received ozanimod 1·0 mg; seven [1·5%] who received ozanimod 0·5 mg; and 16 [3·6%] who received interferon beta-1a)."( Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
Arnold, DL; Bar-Or, A; Cohen, JA; Comi, G; Cree, BAC; Ding, N; Hartung, HP; Kappos, L; Kubala Havrdová, E; Minton, N; Montalban, X; Raghupathi, K; Selmaj, KW; Sheffield, JK; Steinman, L, 2019
)
0.51
" The incidence of treatment-emergent adverse events was higher in the interferon beta-1a group (365 [83·0%] of 440 participants) than in the ozanimod 1·0 mg group (324 [74·7%] of 434) or the ozanimod 0·5 mg group (326 [74·3%] of 439)."( Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
Arnold, DL; Bar-Or, A; Cohen, JA; Comi, G; Cree, BAC; Hartung, HP; Huang, V; Kappos, L; Kubala Havrdová, E; Minton, N; Montalban, X; Raghupathi, K; Selmaj, KW; Sheffield, JK; Steinman, L, 2019
)
0.51
"3% of opicapone-treated patients reported treatment-emergent adverse events (TEAEs) versus 57."( Safety Profile of Opicapone in the Management of Parkinson's Disease.
Ferreira, JJ; Gama, H; Lees, A; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P, 2019
)
0.51
"Long-term use of opicapone once-daily over 1-year at doses of 25 mg or 50 mg was generally safe and well tolerated, supporting its clinical usefulness in the management of PD motor fluctuations."( Safety Profile of Opicapone in the Management of Parkinson's Disease.
Ferreira, JJ; Gama, H; Lees, A; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P, 2019
)
0.51
" Safety assessments included evaluation of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)."( Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.
Lees, A; Magalhães, D; Reichmann, H; Rocha, JF; Soares-da-Silva, P, 2020
)
0.56
" Our study shows that OB exposure causes cardiotoxicity in zebrafish embryos and may be potentially toxic to other aquatic life and even humans."( Exposure to Oxadiazon-Butachlor causes cardiac toxicity in zebrafish embryos.
Cao, Z; Chen, X; Huang, Y; Jiang, P; Liao, X; Liu, Z; Lu, H; Ma, J; Meng, Y; Wang, Z; Wei, Y; Xiao, J; Xie, S; Zhong, K, 2020
)
0.56
" Adverse events were monitored throughout the study."( Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study.
Charles, L; D'Haens, G; Feagan, BG; Ghosh, S; Hanauer, S; Huang, V; Liu, WJ; Petersen, A; Sandborn, WJ; Usiskin, K; Vermeire, S; Wolf, DC, 2021
)
0.62
" The most commonly reported adverse events are dizziness, headache, fatigue, upper respiratory tract infection and urinary tract infection."( Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review.
Antonopoulos, AS; Katsi, V; Michalakeas, C; Soulaidopoulos, S; Tousoulis, D; Tsioufis, K; Vlachopoulos, C, 2021
)
0.62
" Headache and dizziness were the most frequent treatmentrelated treatment-emergent adverse events."( Evaluation of the Efficacy and Safety of Azilsartan in Adult Patients with Essential Hypertension: A Randomized, Phase-III Clinical Study in India.
Agarwal, M; Chary, S; Naik K, S; Reddy Bandi, M; Reddy, VK; Sinha, S; Talluri, L; Thakur, P, 2021
)
0.62
" Safety was monitored via adverse events, laboratory testing, and physical, cardiovascular and neurological examinations."( Long-term safety and efficacy of opicapone in Japanese Parkinson's patients with motor fluctuations.
Hattori, N; Maeda, T; Nishimura, A; Nomoto, M; Takahashi, R; Takeda, A; Tsuboi, Y; Yoshida, K, 2021
)
0.62
"No severe adverse events (AEs) were reported in the dose-escalation stage."( First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat.
Antonijoan, RM; Arévalo, MI; Buesa, C; Coimbra, J; Ferrero-Cafiero, JM; Maes, T; Martínez-Colomer, J; Mascaró, C; Molinero, C; Puntes, M, 2021
)
0.62
"0 mg once daily (OD) and DMF 240 mg twice daily (BID), including confirmed disability progression (CDP) at 3 and 6 months, annualized relapse rate (ARR), proportion of patients relapsed, overall adverse events (AEs), serious AEs (SAEs), and discontinuations due to AEs."( Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
Arndorfer, S; Cohan, S; Kumar, J; Tencer, T; Zhu, X; Zivkovic, M, 2021
)
0.62
"We report pooled incidence and study duration‒adjusted incidence rates (IR) of treatment-emergent adverse events (TEAEs) from an interim data cut (January 31, 2019) of RMS participants treated with ozanimod."( Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program.
Arnold, DL; Bar-Or, A; Cohen, JA; Comi, G; Cree, BAC; Ding, N; Hartung, HP; Havrdova, EK; Kappos, L; Minton, N; Montalban, X; Selmaj, KW; Sheffield, JK; Steinman, L, 2021
)
0.62
" We found that iOWH032 was generally safe and achieved a mean (± standard deviation) plasma level of 4,270 ng/mL (±2,170) after 3 days of oral dosing."( A Phase 2a randomized, single-center, double-blind, placebo-controlled study to evaluate the safety and preliminary efficacy of oral iOWH032 against cholera diarrhea in a controlled human infection model.
Al-Ibrahim, M; Ambler, G; Chen, WH; Choy, RKM; de Hostos, EL; Dong, SD; Erdem, R; Fraczek, K; Gast, C; Mercer, LD; Raine, M; Tennant, SM, 2021
)
0.62
" Most drug-related adverse events (AEs) were mild, with one patient (3."( Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study.
Enya, K; Ito, S; Nishiyama, Y; Sugiura, K, 2022
)
0.72
" This study aimed to elucidate the risk of cardiovascular adverse events (AEs) in patients with multiple sclerosis (MS) treated with S1PR modulators (S1PRMs)."( Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.
Gu, ZC; Lv, Y; Ma, CL; Zhao, Z; Zhong, MK, 2021
)
0.62
" antioxidant and hepato protective activity was investigated on male wistar rats, segregated into four groups as control (NS), toxic (INH-RIF), standard (Silymerin) and sample (OXPA, 100mg/Kg) for 21days."( In silico, in vivo enzymatic, non-enzymatic toxicity and antioxidant activity of a heterocyclic compound: 5-Benzyl -1, 3, 4-oxadiazole-2-thiol, a potential drug candidate.
Abbasi, MA; Ali, E; Bukhari, NI; Chamun, S; Hussain, K; Perveen, S; Qamar, S; Shehzadi, N; Siddique, SZ, 2022
)
0.72
"9%) had treatment-emergent adverse events (TEAEs; similar in nature to those in the parent trials), 298 (11."( Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Arnold, DL; Bar-Or, A; Cheng, CY; Cohen, JA; Comi, G; Cree, BA; Hartung, HP; Havrdová, EK; Kappos, L; Minton, N; Montalbán, X; Selmaj, KW; Sheffield, JK; Silva, D; Steinman, L, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" Repeated administration of [14C]PN 200-110 showed no change in pharmacokinetic characteristics."( Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man.
Jaffe, JM; Tse, FL, 1987
)
0.27
" Nufenoxole was absorbed with an apparent half-life of less than one hour at all three doses."( Single- and multiple-dose pharmacokinetics of nufenoxole in healthy human subjects.
Brownsill, RD; Gerry, N; Hiley, MP; McAllister, A; Rose, DA; Stafford, JE; Steiner, JA; Vose, CW, 1987
)
0.27
"The pharmacokinetic properties and hemodynamic effect of molsidomine and its pharmacologically active metabolite SIN-1 were investigated in 13 healthy volunteers following single oral doses."( Relationship between pharmacokinetics and pharmacodynamics of molsidomine and its metabolites in humans.
Brandstätter, A; Gärtner, W; Jähnchen, E; Meinertz, T; Ostrowski, J; Trenk, D, 1985
)
0.27
" The plasma half-life of molsidomine is 1 to 2 hours: it is not modified in patients with renal failure, but it is prolonged in patients with hepatic failure."( [Human pharmacokinetics of molsidomine].
Martre, H; Singlas, E, 1983
)
0.27
" After oral treatment with 2 mg molsidomine three times daily for 1 week, the pharmacokinetic parameters and the effects on heart rate and blood pressure after the final dose were not different from those after the first dose."( Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study.
Bergstrand, R; Chamberlain, J; Dell, D; Ostrowski, J; Peterson, LE; Stevens, LA; Vedin, A; Wilhelmsson, C, 1984
)
0.27
" Plasma concentration-versus-time data were curve fitted for each subject by using a nonlinear weighted least-squares algorithm, and pharmacokinetic parameters were determined from the polyexponential estimates."( Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution and effect of food.
Abdel-Rahman, SM; Kearns, GL, 1998
)
0.3
" Plasma drug concentration-time data for each subject were fitted to the curve by using a nonlinear, weighted (weight = 1/Ycalc) least-squares algorithm, and model-dependent pharmacokinetic parameters were determined from the polyexponential parameter estimates."( Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution in children and adolescents. Pediatric Pharmacology Research Unit Network.
Abdel-Rahman, SM; Blowey, DL; Jacobs, RF; James, LP; Kearns, GL; Marshall, JD; Wells, TG, 1999
)
0.3
" A significant difference in both Cmax and AUC was observed between study groups; however, this difference became insignificant when the parameters were corrected for dose."( Single oral dose escalation pharmacokinetics of pleconaril (VP 63843) capsules in adults.
Abdel-Rahman, SM; Kearns, GL, 1999
)
0.3
" Pharmacokinetic parameter estimates were determined by noncompartmental methods and compared between doses and with similar data obtained from a previous study of pleconaril disposition in children (n = 18, 2 to 12 years)."( Single dose pharmacokinetics of pleconaril in neonates. Pediatric Pharmacology Research Unit Network.
Abdel-Rahman, SM; Bradley, JS; Capparelli, EV; Jacobs, RF; James, LP; Johnson, KM; Kearns, GL, 2000
)
0.31
" This pharmacodynamic phenomenon is referred to in the present work as "teleantagonism"."( Teleantagonism: A pharmacodynamic property of the primary nociceptive neuron.
Cunha, FQ; Duarte, DB; Ferrari, LF; Ferreira, SH; Funez, MI; Lorenzetti, BB; Parada, CA; Sachs, D, 2008
)
0.35
" We reasoned that an animal model would be suitable for GSI discovery if the pharmacokinetic (PK)/pharmacodynamic (PD) relationship of a compound for Aβ lowering in this model is predictive of that in human."( Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
Atchison, K; Becker, SL; Efremov, I; Hallgren, AJ; Lu, Y; Miller, EH; Nolan, CE; Osgood, SM; Pustilnik, LR; Riddell, D; Robshaw, AE; Stepan, AF; Subramanyam, C; Zhang, L, 2011
)
0.37
" Despite high metabolic stability, pharmacokinetic evaluation revealed poor mice exposure; therefore, a second phase of optimization was required."( Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors.
Baulard, AR; Blondiaux, N; Brodin, P; Christophe, T; Déprez, B; Desroses, M; Flament, MP; Flipo, M; Jeon, HK; Lecat-Guillet, N; Leroux, F; Locht, C; Mathys, V; Piveteau, C; Siepmann, J; Soror, SH; Villemagne, B; Villeret, V; Willand, N; Wintjens, R; Wohlkönig, A, 2012
)
0.38
"The goal of this study was to assess the tolerability profile, pharmacokinetic properties, and effects on pharmacodynamic markers (Aβ, trefoil factor family 3 protein, dual specificity phosphatase 6, and hairy and enhancer of split-1) of single, oral doses of avagacestat in healthy, young, male volunteers."( Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Albright, CF; Berman, RM; Castaneda, L; Croop, R; Dockens, RC; Gu, H; Huang, SP; Li, H; Slemmon, R; Smith, C; Sverdlov, O; Tong, G; Wang, JS; Wong, O, 2012
)
0.38
"The favourable safety profile and pharmacokinetic effects of avagacestat in this study support its continued development, especially in the target population of elderly subjects with mild cognitive impairment or Alzheimer's disease."( A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat.
Albright, CF; Berman, RM; Castaneda, L; Croop, R; Dockens, R; Gu, H; Huang, SP; Li, H; Slemmon, R; Smith, C; Sverdlov, O; Tong, G; Wang, JS; Wong, O, 2013
)
0.39
"Avagacestat was rapidly absorbed, had a terminal elimination half-life of 38-65 h, and reached a steady-state concentration by day 10 of daily dosing."( A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects.
Albright, CF; Berman, RM; Castaneda, L; Dockens, R; Gu, H; Huang, SP; Li, H; Slemmon, R; Smith, C; Sverdlov, O; Tong, G; Wang, JS; Wong, O, 2012
)
0.38
" Based on the observation that the half-life of COMT inhibition is independent of the dose and that it reflects an underlying kinetic process that is consistent with the k(off) value of the COMT-opicapone complex, we propose that the sustained COMT inhibition, far beyond the observable point of clearance of circulating drug, is due to the long residence time of the reversible complex formed between COMT and opicapone."( Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.
Almeida, L; Bonifácio, MJ; Falcão, A; Loureiro, AI; Nunes, T; Palma, PN; Pinto, R; Rocha, JF; Soares-da-Silva, P; Wright, LC, 2013
)
0.39
" Here, to determine and analyze the correlation between the pharmacodynamic (PD) and pharmacokinetic (PK) parameters of ASP2151, we examined the PD profile of ASP2151 using in vitro plaque reduction assay and a murine model of HSV-1 infection."( Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection.
Chono, K; Kato, K; Katsumata, K; Kontani, T; Ohtsu, Y; Suzuki, H; Takakura, S, 2013
)
0.39
" In addition, it remains to be determined whether the specific pharmacologic and pharmacokinetic characteristics of azilsartan will have a clinically significant impact on long-term cardiovascular outcomes."( Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension.
Angeli, F; Pascucci, C; Poltronieri, C; Reboldi, G; Verdecchia, P, 2013
)
0.39
"Based on the pharmacokinetic and tolerability findings, no dose adjustment of AZL-M is required for subjects with any degree of renal impairment, including end-stage renal disease."( Single-center evaluation of the single-dose pharmacokinetics of the angiotensin II receptor antagonist azilsartan medoxomil in renal impairment.
Dudkowski, C; Garg, D; Karim, A; Lenz, O; Preston, RA; Sica, DA; Zhao, Z, 2013
)
0.39
"Opicapone increased levodopa systemic exposure by 2-fold not changing Cmax values and reduced both 3-O-methyldopa (3-OMD) exposure and Cmax values by 5-fold."( Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
Bonifácio, MJ; Soares-da-Silva, P; Sutcliffe, JS; Torrão, L; Wright, LC, 2014
)
0.4
" Although apparent total clearance (CL/F) of opicapone was decreased by ∼35 %, similar elimination half-life and unbound/bound fractions of opicapone were observed between the two groups."( Effect of moderate liver impairment on the pharmacokinetics of opicapone.
Falcão, A; Lopes, N; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P, 2014
)
0.4
" The purpose of this study was to compare the levodopa pharmacokinetic profile throughout a day driven by the COMT inhibition either following repeated doses of opicapone or concomitant administration with entacapone."( Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
Falcão, A; Lopes, N; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P; Vaz-da-Silva, M; Wright, LC, 2014
)
0.4
" Pharmacokinetic parameters remained similar between Days 1 and 8 for each age, sex, and race subgroup."( Effects of Age, Sex, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of Azilsartan Medoxomil in Healthy Subjects.
Dudkowski, C; Harrell, RE; Karim, A; Zhang, W, 2016
)
0.43
"Based on these pharmacokinetic and safety/tolerability findings, no AZL-M dose adjustments are required based on age, sex, or race (black/white)."( Effects of Age, Sex, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of Azilsartan Medoxomil in Healthy Subjects.
Dudkowski, C; Harrell, RE; Karim, A; Zhang, W, 2016
)
0.43
"Population pharmacokinetic and exposure-response models for azilsartan medoxomil (AZL-M) and chlorthalidone (CLD) were developed using data from an 8-week placebo-controlled phase 3, factorial study of 20, 40, and 80 mg AZL-M every day (QD) and 12."( Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension.
Kupfer, S; Tsai, MC; Vakilynejad, M; Wu, J, 2016
)
0.43
" There was a linear relationship between dose and systemic exposure with a dose-independent half-life (t1/2 ) between 44."( Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers.
Gray, F; Henderson, A; Hicks, K; Oliver, J; Thompson, P; Xu, J; Yang, J, 2014
)
0.4
" We present a first population pharmacokinetic (PPK) modeling analysis of Amenamevir for genital herpes patients."( Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes.
Kaibara, A; Katashima, M; Keirns, J; Sawamoto, T; Takada, A; Zhang, W, 2014
)
0.4
" In cohort 1, the fed-fasted ratios for AUC0-inf and Cmax were 108."( Effects of Food Intake on the Pharmacokinetics of Azilsartan Medoxomil and Chlorthalidone Alone and in Fixed-Dose Combination in Healthy Adults.
Dudkowski, C; Karim, A; Munsaka, M, 2016
)
0.43
"To compare the levodopa/carbidopa (LC) and levodopa/benserazide (LB) pharmacokinetic profiles following repeated doses of opicapone (OPC) administered apart from levodopa."( Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
Almeida, L; Bonifácio, MJ; Falcão, A; Fauchoux, N; Loureiro, AI; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Sicard, É; Soares-da-Silva, P, 2017
)
0.46
" The combination of AZ and CLT had greater BP lowering effect compared to AZ or CLT alone, despite of no pharmacokinetic interaction between two drugs."( Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats.
Bhateria, M; Bhatta, RS; Hanif, K; Jain, M; Kumar Puttrevu, S; Ramakrishna, R, 2017
)
0.46
" After quantifying opicapone and BIA 9-1079 in plasma, a non-compartmental pharmacokinetic analysis was performed."( Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat.
Alves, G; Falcão, A; Fortuna, A; Gonçalves, D; Soares-da-Silva, P, 2017
)
0.46
" Despite having a short elimination half-life (≤2."( A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat.
Alves, G; Bonifácio, MJ; Falcão, A; Fortuna, A; Gonçalves, D; Soares-da-Silva, P, 2017
)
0.46
" Based on the pharmacokinetic and tolerability findings, no dose adjustment of AZL-M is required for subjects with mild and moderate hepatic impairment."( Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment.
Alonso, AB; Dudkowski, C; Garg, D; Karim, A; Preston, RA; Zhao, Z, 2018
)
0.48
" 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) is a non-invasive pharmacodynamic imaging biomarker that has become an integral part of drug development."( The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Barjat, H; Ble, FX; Emmas, SA; Hancox, U; Hudson, K; Lawrie, E; Maynard, J; Polanska, UM; Pritchard, A, 2017
)
0.46
"Our pre-clinical studies support the use of 18F-FDG PET imaging as a sensitive and non- invasive pharmacodynamic biomarker (understanding the role of PI3K signalling in glucose uptake) for AZD8835 with a decrease in 18F-FDG uptake observed at only two hours post treatment."( The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Barjat, H; Ble, FX; Emmas, SA; Hancox, U; Hudson, K; Lawrie, E; Maynard, J; Polanska, UM; Pritchard, A, 2017
)
0.46
"Amenamevir had less than dose proportional pharmacokinetic characteristics."( Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies.
den Adel, M; Groenendaal-van de Meent, D; Katashima, M; Keirns, JJ; Kowalski, D; Kusawake, T; Ohtsu, Y; Takada, A, 2017
)
0.46
"In the hepatic impairment study, the pharmacokinetic profile of amenamevir in participants with moderate hepatic impairment was generally similar to that of participants with normal hepatic function."( The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.
Katashima, M; Kato, K; Keirns, JJ; Kowalski, D; Kusawake, T; Lasseter, KC; Lewand, M; Marbury, TC; Preston, RA; Takada, A, 2017
)
0.46
" However, it is unlikely that renal impairment will have a significant effect on the safety of amenamevir given that in previous pharmacokinetic and safety studies in healthy individuals amenamevir was safe and well tolerated after a single dose (5-2400 mg, fasted condition) and repeated doses for 7 days (300 or 600 mg, fed condition), and the amount of amenamevir exposure in the renal impairment study was covered by those studies."( The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.
Katashima, M; Kato, K; Keirns, JJ; Kowalski, D; Kusawake, T; Lasseter, KC; Lewand, M; Marbury, TC; Preston, RA; Takada, A, 2017
)
0.46
" Areas covered: The purpose of this study was to evaluate pharmacokinetic of OPC for the treatment of PD."( Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease.
Kostić, V; Kresojević, N; Svetel, M; Tomić, A, 2018
)
0.48
"  Amenamevir increased peak concentration and area under the concentration-time curve of montelukast by about 22% (ratio 121."( Amenamevir: Studies of Potential CYP2C8- and CYP2B6-Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers.
Adeloye, T; Dennison, J; Endo, T; Johnston, A; Puri, A; Warrington, S, 2018
)
0.48
" The present study aimed to evaluate the safety and pharmacokinetic properties of AZL in healthy Chinese subjects."( Clinical Evaluation of the Tolerability and Pharmacokinetics of Azilsartan, a Potent Angiotensin Receptor Blocker, in Healthy Chinese Subjects.
Chen, G; Chen, H; Cui, D; Ding, Y; Guo, Y; Jiao, Z; Li, C; Li, X; Liu, J; Shen, Z; Sheng, C; Wu, M; Zhang, H; Zhu, X, 2020
)
0.56
" The median terminal elimination half-life within 24 h before, during, and after hemodialysis was 14."( Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients.
Endo, T; Hashimoto, N; Seo, M; Tsuruoka, S, 2020
)
0.56
"The aims of this study were to characterize the multiple-dose pharmacokinetics (PK) of ozanimod's major active metabolites (CC112273 and CC1084037) and to evaluate the pharmacodynamic and PK interactions with pseudoephedrine (PSE)."( Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects.
Ghosh, A; Harris, S; Palmisano, M; Syto, M; Tran, JQ; Walker, S; Wang, X; Zhang, P, 2020
)
0.56
"The study aimed to determine the safety and tolerability of vafidemstat, to characterize its pharmacokinetic and pharmacodynamic profiles, to assess its central nervous system (CNS) exposure, and to acquire the necessary data to select the appropriate doses for long-term treatment of patients with CNS disease in phase II trials."( First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat.
Antonijoan, RM; Arévalo, MI; Buesa, C; Coimbra, J; Ferrero-Cafiero, JM; Maes, T; Martínez-Colomer, J; Mascaró, C; Molinero, C; Puntes, M, 2021
)
0.62
" To investigate the preclinical pharmacokinetic (PK) properties of three candidate compounds (CY-14S-4A83, CY-16S-4A43, and CY-16S-4A93), liquid chromatography, in tandem with the mass spectrometry LC-MS/MS method, was developed and validated for the simultaneous determination of these compounds."( Pharmacokinetics of Novel Furoxan/Coumarin Hybrids in Rats Using LC-MS/MS Method and Physiologically Based Pharmacokinetic Model.
Cai, W; Chen, Y; He, Q; Li, Z; Liu, L; Peng, C; Tang, Z; Wang, K; Xiang, X; Yuan, Y; Zhang, S; Zhu, X, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
"Experiments were carried out to study the effect of sydnocarb 3-(beta-phenylisopropyl)-N-phenylcarbamoyl-sydnonimine), a stimulant of mental and physical performance, and its combination with obsidan, a beta-adrenoblocking agent, on the central and peripheral hemodynamics during a head-up test (+75 degrees) after a 6-hour head-down tilt (-15 degrees)."( [Posture-related changes in hemodynamics in humans after administration of sidnocarb and its combination with obsidan].
Degterenkova, NV; Gornago, VA; Modin, AIu; Shashkov, BS; Sokolov, VI,
)
0.13
") was administered in combination with WAY100635 (0."( Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo.
Gartside, SE; Sharp, T; Umbers, V, 1997
)
0.3
" This study provides a direct comparison of chlorthalidone with hydrochlorothiazide, each combined with the angiotensin receptor blocker azilsartan medoxomil, on blood pressure reduction and control rates."( Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
Bakris, GL; Cushman, WC; Handley, A; Kupfer, S; Sica, D; Song, E; Weber, MA; White, WB, 2012
)
0.38
"Chlorthalidone combined with azilsartan medoxomil provides better blood pressure reduction and a higher likelihood of achieving blood pressure control than hydrochlorothiazide combined with azilsartan medoxomil."( Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil.
Bakris, GL; Cushman, WC; Handley, A; Kupfer, S; Sica, D; Song, E; Weber, MA; White, WB, 2012
)
0.38
" In both animal models the anti-lymphoma activity of selinexor is enhanced through combination with DEX or EVER."( Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Aboukameel, A; Azmi, AS; Baloglu, E; Bhutani, D; Carlson, R; Elloul, S; Kauffman, M; Mohammad, RM; Muqbil, I; Senapedis, W; Shacham, S; Zonder, J, 2016
)
0.43
" Here we investigated the combined treatment modality of the novel MTA BAL101553 in combination with radiotherapy in paclitaxel and epothilone-resistant tumor models."( The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.
Bachmann, F; Broggini-Tenzer, A; Guckenberger, M; Lane, HA; Messikommer, A; Nytko, KJ; Pruschy, M; Sharma, A; Vuong, V, 2017
)
0.46
"Multiple regimens of BAL101553, or its active moiety BAL27862 for in vitro experiments, were probed in combination with radiotherapy in P-glycoprotein-overexpressing, human colon adenocarcinoma cells (SW480) and in tubulin-mutated human NSCLC cells (A549EpoB40) and tumors thereof."( The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.
Bachmann, F; Broggini-Tenzer, A; Guckenberger, M; Lane, HA; Messikommer, A; Nytko, KJ; Pruschy, M; Sharma, A; Vuong, V, 2017
)
0.46
" Azilsartan medoxomil in combination with the older diuretic chlorthalidone (CLD) in fixed-doses of AZM/CLD 40/12."( Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review.
Antonopoulos, AS; Katsi, V; Michalakeas, C; Soulaidopoulos, S; Tousoulis, D; Tsioufis, K; Vlachopoulos, C, 2021
)
0.62

Bioavailability

Oxadiazoles are potent and orally bioavailable beta3 adrenergic receptor (AR) agonists. They are excellent tools for studying the role of HDAC6 in vitro and in vivo in rats and mice.

ExcerptReferenceRelevance
" Nufenoxole, a novel antidiarrhoeal agent, was well absorbed in rat, monkey and human after oral administration."( Metabolism and pharmacokinetics of nufenoxole in animals and humans: an example of stereospecific hydroxylation of an isoquinuclidine ring.
Campion, JG; Cook, CS; Hribar, JD; Karim, A, 1990
)
0.28
" PN 200-110 was rapidly and almost completely (90-95%) absorbed from the gastrointestinal tract, although the estimated bioavailability was only 17% due to extensive first-pass metabolism."( Pharmacokinetics of PN 200-110 (isradipine), a new calcium antagonist, after oral administration in man.
Jaffe, JM; Tse, FL, 1987
)
0.27
" Its absolute bioavailability (44 +/- 15%) and a 14C-labeled triale give evidence of quick biotransformation of molsidomine to active metabolites."( Pharmacokinetics of molsidomine in humans.
Ostrowski, J; Resag, K, 1985
)
0.27
"Molsidomine is well absorbed by the gastro-intestinal tract and is taken up by the liver during the first passage."( [Human pharmacokinetics of molsidomine].
Martre, H; Singlas, E, 1983
)
0.27
" Additionally, plasma concentrations of molsidomine were determined to elucidate the bioavailability as well as possible correlations between plasma concentrations and antiischemic effect."( [Anti-ischemic effect of 8 mg molsidomin in retard form].
Blasini, R; Brügmann, U; Rudolph, W, 1984
)
0.27
" The bioavailability of a 2 mg oral dose of molsidomine was 44%."( Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study.
Bergstrand, R; Chamberlain, J; Dell, D; Ostrowski, J; Peterson, LE; Stevens, LA; Vedin, A; Wilhelmsson, C, 1984
)
0.27
" BTI 2571E had approximately 40% bioavailability after oral administration."( Pharmacokinetics and amoebicidal activity of (+-)-(E)-3-(4- methylsulphinylstyryl)-1,2,4-oxadiazole (BTI 2286E) and its sulphone metabolite (BTI 2571E) in the golden hamster, Mesocricetus auratus.
Bhopale, KK; Kaul, CL; Kelkar, MG; Pargal, A; Phaltankar, PG, 1993
)
0.29
" Increasing bioavailability has been achieved with greater lipophilicity and thus the potential for greater activity in the central nervous system."( Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT(1B/1D)) receptors.
Goadsby, PJ; Knight, Y, 1997
)
0.3
" The apparent bioavailability of pleconaril oral solution was significantly increased with the administration of food."( Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution and effect of food.
Abdel-Rahman, SM; Kearns, GL, 1998
)
0.3
"Pleconaril (VP 63843) is a novel orally bioavailable small molecule with broad antipicornavirus (enterovirus and rhinovirus) activity."( Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants.
Groarke, JM; Pevear, DC, 1999
)
0.3
" The compound has high oral bioavailability in dogs (62%) and rats (36%) and is among the most orally bioavailable beta3 adrenergic receptor agonists reported to date."( Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist.
Biftu, T; Candelore, MR; Cascieri, MA; Colwell, LF; Deng, L; Feeney, WP; Feng, DD; Fisher, MH; Forrest, MJ; Hom, GJ; MacIntyre, DE; Miller, RR; Stearns, RA; Strader, CD; Tota, L; Weber, AE; Wyvratt, MJ, 2000
)
0.31
"Benzyl and phenoxymethylene substituted oxadiazoles are potent and orally bioavailable beta3 adrenergic receptor (AR) agonists."( Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents.
Biftu, T; Candelore, MR; Cascieri, MA; Colandrea, VJ; Colwell, LF; Feng, DD; Fisher, MH; Forrest, MJ; Hom, GJ; Kuo, H; Liang, GB; MacIntyre, DE; Naylor, EM; Qian, X; Stearns, RA; Strader, CD; Weber, AE; Wyvratt, MJ, 2000
)
0.57
"The apparent age-dependent differences in the pharmacokinetics of pleconaril may in part be related to increased bioavailability of the drug in older children and adults than in neonates."( Single dose pharmacokinetics of pleconaril in neonates. Pediatric Pharmacology Research Unit Network.
Abdel-Rahman, SM; Bradley, JS; Capparelli, EV; Jacobs, RF; James, LP; Johnson, KM; Kearns, GL, 2000
)
0.31
" Pleconaril is orally bioavailable and achieves serum concentrations in excess of those required to inhibit 90% of clinical rhino- and enteroviral isolates in vitro."( Pleconaril: a novel antipicornaviral drug.
Romero, JR, 2001
)
0.31
"N-acetyl-L-cysteine exerts direct anti-aggregating effects through an increased bioavailability of platelet nitric oxide."( N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets.
Anfossi, G; Cavalot, F; Massucco, P; Mattiello, L; Russo, I; Trovati, M, 2001
)
0.31
" High glucose inhibits nitric oxide (NO) bioavailability and decreased NO increases TGF-beta activity and extracellular matrix accumulation."( Nitric oxide and cGMP-dependent protein kinase regulation of glucose-mediated thrombospondin 1-dependent transforming growth factor-beta activation in mesangial cells.
Darley-Usmar, V; Murphy-Ullrich, JE; Poczatek, MH; Shiva, S; Wang, S, 2002
)
0.31
"ONO-6818 (CP-955) is the lead compound in a series of orally bioavailable neutrophil elastase inhibitors licensed from Cortech and under investigation by Ono for the potential treatment of inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease and chronic obstructive pulmonary disease (COPD) [174095]."( ONO-6818 Cortech/Ono.
Trifilieff, A, 2002
)
0.31
" Replacement of the C6-ester substituent of the pyrrolo[2,1-f][1,2,4]triazine core with heterocyclic bioisosteres, such as substituted 1,3,5-oxadiazoles, afforded compounds with excellent oral bioavailability in mice (i."( Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
Barrish, JC; Bhide, RS; Borzilleri, RM; Cai, ZW; Ellis, C; Fargnoli, J; Fura, A; Hunt, JT; Jeyaseelan, R; Kamath, A; Kukral, DW; Lombardo, LJ; Mortillo, S; Qian, L; Tokarski, JS; Vyas, V; Wautlet, BS; Zheng, X, 2005
)
0.53
"Acute respiratory distress syndrome (ARDS) is associated with increased superoxide (O(2)(*-)) formation in the pulmonary vasculature and negation of the bioavailability of nitric oxide (NO)."( Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells.
Angelini, GD; Jeremy, JY; Muzaffar, S; Shukla, N; Srivastava, A, 2005
)
0.33
" Nonetheless, DM may cause uncoupling of nitric oxide synthases (NOSs) with reduction in the bioavailability of nitric oxide (NO), which is critical to maintain oocyte viability and prevent aging."( Activation of the cGMP signaling pathway is essential in delaying oocyte aging in diabetes mellitus.
Abu-Soud, HM; Diamond, MP; Gonik, B; Goud, AP; Goud, PT, 2006
)
0.33
" This study provides the first evidence that increased denitrosylation leads to increased bioavailability of NO, independent of NOS activity, to promote sustained angiogenesis."( The release of nitric oxide from S-nitrosothiols promotes angiogenesis.
Ahmad, S; Ahmed, A; Ahmed, S; Al-Ani, B; Cudmore, M; Fujisawa, T; Hewett, PW, 2006
)
0.33
" The selectivity of PTC124 for premature termination codons, its well characterized activity profile, oral bioavailability and pharmacological properties indicate that this drug may have broad clinical potential for the treatment of a large group of genetic disorders with limited or no therapeutic options."( PTC124 targets genetic disorders caused by nonsense mutations.
Almstead, NG; Babiak, J; Barton, ER; Branstrom, AA; Campbell, JA; Chen, G; Colacino, JM; Conn, MM; Corson, D; Feng, H; Friesen, WJ; He, F; Hedrick, J; Hirawat, S; Hwang, S; Jacobson, A; Jones, S; Ju, WD; Karp, G; Kawana, M; Khan, A; Miller, LL; Mollin, A; Moon, YC; Northcutt, VJ; Patel, M; Paushkin, S; Peltz, SW; Ren, H; Risher, N; Spatrick, P; Sweeney, HL; Takasugi, J; Tomizawa, Y; Trifillis, P; Trotta, CR; Turpoff, AA; Weetall, M; Welch, EM; Wilde, RG; Yeh, S; Zhuo, J, 2007
)
0.34
" In this work, we have discovered a series of potent, selective, orally bioavailable SCD1 inhibitors based on a known pyridazine carboxamide template."( Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors.
Beno, DW; Camp, HS; Cao, N; Cepa, SP; Collins, CA; Freeman, J; Janis, RS; Krauser, JA; Kym, PR; Liu, B; Liu, G; Lynch, JK; Serby, MD; Sham, HL; Smith, HT; Suhar, TS; Surowy, TK; Xin, Z; Yang, R; Zhao, H, 2007
)
0.34
" PTC124 is an orally bioavailable compound that promotes readthrough of premature translation termination codons, suggesting that it may have the potential to treat genetic diseases caused by nonsense mutations."( PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model.
Bedwell, DM; Du, M; Hirawat, S; Liu, X; Peltz, SW; Welch, EM, 2008
)
0.35
" Since nitric oxide bioavailability is decreased in sickle cell disease and nitric oxide may inhibit leukocyte adhesion, we investigated whether stimulation of NO-signaling pathways can reduce the adhesive properties of neutrophils from sickle cell disease individuals (sickle cell diseaseneu)."( Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation.
Canalli, AA; Conran, N; Costa, FF; Franco-Penteado, CF; Saad, ST, 2008
)
0.35
" PTC124 is an orally bioavailable small molecule that is designed to induce ribosomes to selectively read through premature stop codons during mRNA translation, to produce functional CFTR."( Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.
Armoni, S; Aviram, M; Blau, H; Cohen, M; Elfring, GL; Hirawat, S; Kerem, B; Kerem, E; Miller, LL; Nissim-Rafinia, M; Northcutt, VJ; Rivlin, J; Shoseyov, D; Wilschanski, M; Yaakov, Y, 2008
)
0.35
" As a result a novel series of oxadiazole CGRP receptor antagonists has been identified and the subsequent optimisation to enhance both potency and bioavailability is presented."( Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine.
Brand, J; Briggs, M; D'Angeli, M; Farge, J; Garland, SL; Goldsmith, P; Hutchings, R; Kilford, I; Li, HY; MacPherson, D; Nichols, PL; Nimmo, F; Sanderson, FD; Sehmi, S; Shuker, N; Skidmore, J; Stott, M; Sweeting, J; Tajuddin, H; Takle, AK; Trani, G; Wall, ID; Ward, R; Wilson, DM; Witty, D, 2010
)
0.36
" Furthermore, one selected compound was tested for peroral bioavailability in mice."( 1-(5-Carboxyindol-1-yl)propan-2-one inhibitors of human cytosolic phospholipase A2α: effect of substituents in position 3 of the indole scaffold on inhibitory potency, metabolic stability, solubility, and bioavailability.
Bovens, S; Kaptur, M; Lehr, M; Reinhardt, D; Schäfers, M; Schulze Elfringhoff, A, 2010
)
0.36
" The present study demonstrated that iNOS-derived superoxide generation was reduced, and that the NO bioavailability was increased, by treatment with the NOS-cofactor, tetrahydrobiopterin (BH4), before I/R in the hearts isolated from diabetic rats."( Reversal of inducible nitric oxide synthase uncoupling unmasks tolerance to ischemia/reperfusion injury in the diabetic rat heart.
Fujita, M; Ito, S; Iwasaka, T; Katano, T; Okazaki, T; Otani, H; Shimazu, T; Yoshioka, K, 2011
)
0.37
" The compound was well absorbed and its primary route of elimination was in the feces."( Metabolism of [(14)C]GSK977779 in rats and its implication with the observed covalent binding.
Deng, Y; Gorycki, PD; Hardesty, WM; Madatian, A; Schubert, EM; Seymour, JL; Tsalta, CD; Xia, F, 2011
)
0.37
"Novel, low brain penetrant, orally bioavailable CB1 receptor agonists were designed starting from a mature lead series of potent brain penetrant CB1 receptor agonists."( Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain.
Adam, JM; Baker, J; Boyce, S; Campbell, R; Clark, JK; Cottney, JE; Davies, K; Deehan, M; Everett, K; Fields, R; Francis, S; Jeremiah, F; Kiyoi, T; Maidment, M; Martin, I; Morrison, A; Prosser, A; Ratcliffe, P; Schulz, J; Wishart, G, 2012
)
0.38
"A methodology for the accurate calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) assays and its application in supporting microdose absolute bioavailability studies are reported for the first time."( Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies.
Arnold, ME; Aubry, AF; Bifano, M; Burrell, R; Dockens, R; Easter, J; Gu, H; Jiang, H; Wang, J; Wang, JS; Zeng, J, 2012
)
0.38
"The manuscript reports an identification of a highly potent, orally bioavailable hepatitis C virus entry inhibitor through optimization of a previously reported class of molecules (1) that were not stable in the rat plasma."( Discovery of ITX 4520: a highly potent orally bioavailable hepatitis C virus entry inhibitor.
Chow, S; Gao, H; Jackson, A; Kaur, MP; Lee, H; Macdonald, JE; McKelvy, J; Mittapalli, GK; Nguyen, N; Wong-Staal, F; Zamboni, R; Zhao, F, 2012
)
0.38
" Incorporation of a 1,2,4-oxadiazole linker and substitution of the pendant phenyl ring led to the discovery of orally bioavailable analogues that showed efficient NR2B receptor occupancy in rats."( Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists.
Bednar, RA; Cunningham, ME; Dilella, AG; Fandozzi, C; Fay, JF; Kelly, MJ; Koblan, KS; Layton, ME; Liang, A; Lis, EV; McDonald, TP; Mosser, SD; Reiss, DR; Rodzinak, KJ; Sanderson, PE; Seabrook, GR; Trainor, N; Urban, MO; Wang, H; Yergey, J; Young, SD, 2011
)
0.37
" It is a prodrug that is quickly hydrolyzed to the active moiety azilsartan, a potent and highly selective angiotensin-receptor blocker with estimated bioavailability of ∼ 60%."( Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension.
Angeli, F; Pascucci, C; Poltronieri, C; Reboldi, G; Verdecchia, P, 2013
)
0.39
" These results suggest that BAY 60-2770 would be effective in the treatment of erectile dysfunction when NO bioavailability is reduced, after pelvic nerve injury, and when sGC is oxidized."( The sGC activator BAY 60-2770 has potent erectile activity in the rat.
Frink, TJ; Kadowitz, PJ; Lasker, GF; Pankey, EA; Walter, KA; Zeitzer, JR, 2013
)
0.39
" It exhibits oral bioavailability and limited toxicity in human trials."( Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension.
Aldred, MA; Drake, KM; Dunmore, BJ; McNelly, LN; Morrell, NW, 2013
)
0.39
"The present study aimed at evaluating the effect of opicapone, a third generation nitrocatechol catechol-O-methyltransferase (COMT) inhibitor, on the systemic and central bioavailability of 3,4-dihydroxy-l-phenylalanine (levodopa) and related metabolites in the cynomolgus monkey."( Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
Bonifácio, MJ; Soares-da-Silva, P; Sutcliffe, JS; Torrão, L; Wright, LC, 2014
)
0.4
"The bioavailability of an orally administered single dose of 50 mg OPC was significantly higher in patients with moderate chronic hepatic impairment, perhaps by a reduced first-pass effect."( Effect of moderate liver impairment on the pharmacokinetics of opicapone.
Falcão, A; Lopes, N; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P, 2014
)
0.4
"Opicapone, a novel third generation COMT inhibitor, when compared to entacapone, provides a superior response upon the bioavailability of levodopa associated to more pronounced, long-lasting, and sustained COMT inhibition."( Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
Falcão, A; Lopes, N; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Soares-da-Silva, P; Vaz-da-Silva, M; Wright, LC, 2014
)
0.4
"Opicapone has a prolonged inhibitory effect on peripheral COMT, which extends the bioavailability of levodopa, without inducing toxicity."( Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
Bonifácio, MJ; Loureiro, AI; Palma, PN; Soares-da-Silva, P; Torrão, L; Wright, LC, 2015
)
0.42
" This antibiotic is bactericidal and is orally bioavailable in mice."( Structure-activity relationship for the oxadiazole class of antibiotics.
Antunes, NT; Boudreau, MA; Chang, M; Ding, D; Lastochkin, E; Leemans, E; Lichtenwalter, K; Mobashery, S; O'Daniel, PI; Peng, Z; Pi, H; Schroeder, VA; Song, W; Spink, E; Suckow, MA; Testero, SA; Vakulenko, S; Wolter, WR, 2015
)
0.42
" This compound had moderate clearance and bioavailability in rat (CL=2."( The discovery and optimization of aminooxadiazoles as potent Pim kinase inhibitors.
Andrews, KL; Cee, V; Chavez, F; Guerrero, N; Herberich, B; Jackson, C; Lanman, BA; Laszlo, J; Lee, MR; Lipford, JR; Mohr, C; Nguyen, Y; Nixey, T; Pettus, LH; Reed, AB; Reid, DL; Sastri, C; Tasker, AS; Wang, HL; Wang, P; Winston, J; Wu, B; Wurz, RP; Xu, Y; Zhou, Y, 2015
)
0.69
" The constructed library shows reasonable, oral bioavailability drug properties as determine by using the Lipinski's Rule and similar parameters."( A Highly Efficient Diversification of 2-Amino/Amido-1,3,4-oxadiazole and 1,3,4-Thiadiazole Derivatives via Reagent-Based Cyclization of Thiosemicarbazide Intermediate on Solid-Phase.
Abdildinova, A; Choe, JH; Gong, YD; Yang, SJ, 2015
)
0.42
" RPC1063 showed high oral bioavailability and volume of distribution, and a circulatory half-life that supports once daily dosing."( Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.
Boehm, MF; Brahmachary, E; Brooks, J; Clemons, B; Dedman, H; Desale, HG; Martinborough, E; Peach, RJ; Powell, R; Roberts, E; Rosen, H; Scott, FL; Timony, GA, 2016
)
0.43
" Much progress has been made over the past decade with the development of orally bioavailable small molecule drugs that target defective CFTR proteins caused by specific mutations."( New and emerging targeted therapies for cystic fibrosis.
Quon, BS; Rowe, SM, 2016
)
0.43
" The bioavailability (BA) of different formulations and effects of food were also evaluated."( Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers.
Gray, F; Henderson, A; Hicks, K; Oliver, J; Thompson, P; Xu, J; Yang, J, 2014
)
0.4
"Opicapone, as once-daily oral evening regimen and/or 1 h apart from levodopa therapy, increases the bioavailability of levodopa associated with its pronounced, long-lasting and sustained catechol-O-methyltransferase inhibition."( Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics.
Almeida, L; Bonifácio, MJ; Falcão, A; Fauchoux, N; Loureiro, AI; Nunes, T; Pinto, R; Rocha, JF; Santos, A; Sicard, É; Soares-da-Silva, P, 2017
)
0.46
"Resveratrol (RVT) is a stilbene with a protective effect on the cardiovascular system; however, drawbacks including low bioavailability and fast metabolism limit its efficacy."( Synthesis, antiplatelet and antithrombotic activities of resveratrol derivatives with NO-donor properties.
Chin, CM; Dos Santos, JL; Dutra, LA; Guanaes, JFO; Johmann, N; Lopes Pires, ME; Marcondes, S, 2017
)
0.46
"Opicapone is a third generation, highly potent and effective catechol O‑methyltransferase (COMT) inhibitor that optimizes the pharmacokinetics and bioavailability of L-DOPA therapy."( Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.
Ferreira, J; Lees, AJ; Poewe, W; Rascol, O; Reichmann, H; Stocchi, F; Tolosa, E, 2017
)
0.46
"Four randomized phase 1 studies investigated the safety and pharmacokinetics of single and multiple doses of amenamevir, including the assessment of age group effect (nonelderly vs elderly), food effect, and the relative bioavailability of two formulations."( Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies.
den Adel, M; Groenendaal-van de Meent, D; Katashima, M; Keirns, JJ; Kowalski, D; Kusawake, T; Ohtsu, Y; Takada, A, 2017
)
0.46
" Bioavailability was 40% after single oral administration."( Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents.
Noguchi, K; Ohtsu, Y; Susaki, Y, 2018
)
0.48
" These compounds did not violate Lipinski's rule, making them potential orally bioavailable anticancer agents."( Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors.
Akalın Çiftçi, G; Altıntop, MD; Kaplancıklı, ZA; Özdemir, A; Sever, B; Turan-Zitouni, G, 2018
)
0.48
" It was originated from DS-chemical library and optimized in the aspect of bioavailability and safety."( [The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus].
Matsumoto, K; Shimada, T; Yoshitomi, T, 2018
)
0.48
" However, oxidative degradation and low bioavailability limit their exogenous application as fungicides on crops."( Synthesis and antifungal activities of novel thiophene-based stilbene derivatives bearing an 1,3,4-oxadiazole unit.
He, D; Jian, W; Shang, J; Wen, L, 2019
)
0.51
" Opicapone fills the unmet need for a compound with sustained COMT inhibition which will improve levodopa bioavailability in patients with Parkinson's disease."( Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration.
Bonifácio, MJ; Kitajima, T; Mizote, S; Moser, P; Soares-da-Silva, P; Tanaka, M; Umemura, T; Yoneda, K, 2018
)
0.48
" These compounds were found to be orally bioavailable and highly effective."( Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
Eswaran, S; Narayanan, S; Shivarudraiah, P; Shruthi, TG; Subramanian, S, 2019
)
0.51
"Oxadiazole replacement of an amide linkage in an RARα agonist template 1, followed by lead optimisation, has produced a highly potent and selective RARβ agonist 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (10) with good oral bioavailability in the rat and dog."( Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury.
Barret Kalindjian, S; Borthwick, AD; Brown, JT; Carlstedt, T; Clarke, E; Corcoran, JPT; Goncalves, MB; Grist, J; Hobbs, C; Jack, J; Jarvis, CI; Mills, M; Mumford, P; Pitcher, T, 2019
)
0.51
" Opicapone is a recent and selective third-generation COMT inhibitor which achieves marked increase in the bioavailability of levodopa."( Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts.
García Ruiz-Espiga, P; Linazasoro-Cristóbal, G; López Del Val, LJ; López-Manzanares, L; Luquin-Piudo, MR; Martínez-Castrillo, JC; Mir, P; Pagonabarraga-Mora, J, 2020
)
0.56
" Herein, we describe the optimization of a series of potent, selective, and orally bioavailable TRPA1 small molecule antagonists, leading to the discovery of a novel tetrahydrofuran-based linker."( Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron Microscopy.
Balestrini, A; Baumgardner, M; Beaumier, F; Chen, H; Chen, J; Chen, Y; Chou, KJ; Ciblat, S; Constantineau-Forget, L; Cridland, AP; Déry, M; Grand-Maître, C; Hackos, DH; Hu, B; Johnson, K; La, H; Larouche-Gauthier, R; Lee, WP; Lépissier, L; Liu, J; Lu, A; Ly, JQ; Magnuson, S; Reese, RM; Riol-Blanco, L; Rohou, A; Rougé, L; Safina, BS; Shields, SD; Shore, DG; Sturino, C; Suto, E; Terrett, JA; Villemure, E; Volgraf, M; Wang, Y; Ward, SI; Wu, X; Zhang, J, 2021
)
0.62
" Levodopa bioavailability and its maximum concentration were higher with opicapone."( Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Müller, T; Schlegel, E; Thiede, HM; Zingler, S, 2022
)
0.72
" And the pharmacokinetic results showed that AZL-NA cocrystal could significantly improve the bioavailability of AZL."( Azilsartan-nicotinamide cocrystal: Preparation, characterization and in vitro / vivo evaluation.
Geng, X; Jin, T; Xiao, Y; Zhu, X, 2022
)
0.72
" However, the oxadiazoles demonstrate high oral bioavailability and low in vivo clearance and are excellent tools for studying the role of HDAC6 in vitro and in vivo in rats and mice."( Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism.
Åstrand, A; Collins, M; Ek, M; Gunnarsson, A; Hughes, G; Johansson, J; Jung, B; Li, Q; Llinas, A; Mogemark, M; Novén, A; Pemberton, N; Ripa, L; Sandmark, J; Shamovsky, I; Tångefjord, S; Xiong, Y, 2023
)
1.27

Dosage Studied

ExcerptRelevanceReference
"001) respectively after a single oral dosage of 5 to 15 mg PR--G 138."( Clinical evaluation of a new antihypertensive vasodilating agent PR--G 138 Cl.
Dorhout Mees, EJ; Vos, J, 1979
)
0.26
" The normalizing effect was further increased by raising the dosage ot 1 mg or 2 mg respectively."( [The normalizing effect of ECG in exercise tolerance tests under molsidomine in different dosages (author's transl].
Jansen, E; Klepzig, H, 1978
)
0.26
" At the earliest the electrographic effects were recorded in the cortical structures of the rabbit's brain, but proved most intensive in the limbic structures, when the dosage of the drug was increased up to 15-40 mg/kg."( [Experimental analysis of the effects of the psychostimulant sydnocarb].
Luk'ianova, SN; Mekhedova, AIa,
)
0.13
"The herbicide oxadiazon, 2-(tert-butyl)-4-(2,4-dichloro-5-isopropyloxy-phenyl)-delta 2-1,3,4-oxadiazoline 5-one, was fed in a total diet at three dosage levels to groups of dairy cows (0."( Residue uptake and depletion measurements of dietary oxadiazon in mammalian and avian species.
Gallo, MA; Guardigli, A; Lefar, MS, 1976
)
0.26
"One of the principal uses of microencapsulation for pharmaceuticals has been the preparation of sustained-release dosage forms which have been usually presented in the form of a suspension or gel."( Sustained-release dosage form of oxolamine citrate: preparation and release kinetics.
Güneri, T; Kendirci, A; Kirilmaz, L,
)
0.13
" The dose-response relationship of quisqualate acting at the N-methyl-D-aspartate (NMDA) receptor was measured as that portion of the whole-cell current activated by quisqualate that could be blocked by the addition of two NMDA antagonists, 5-fluoroindole-2-carboxylic acid, a competitive antagonist of the NMDA receptor-associated glycine site, and D-2-amino-5-phosphonovalerate, a competitive NMDA binding site antagonist."( Quisqualate activates N-methyl-D-aspartate receptor channels in hippocampal neurons maintained in culture.
Grudt, TJ; Jahr, CE, 1990
)
0.28
" Although the dose-response curve is hyperbolic with an ED50 of 78 microM, glutamate apparently activates 2 types of receptors on motoneurons."( Characterization of excitatory amino acid receptors expressed by embryonic chick motoneurons in vitro.
Fischbach, GD; O'Brien, RJ, 1986
)
0.27
" However, in rings with denuded endothelium, pretreatment with (-)-R202-791 resulted in a rightward shift of the dose-response curve to (+)-S202-791, and a depression of the maximal contraction compared with controls."( A possible role for the endothelium in porcine coronary smooth muscle responses to dihydropyridine calcium channel modulators.
Baik, YH; Koch, WJ; Schwartz, A; Williams, JS, 1987
)
0.27
" With increasing ketamine concentration (5 x 10(-5)-10(-3) mol l-1), the amplitude of glutamate potentials was reduced and dose-response curves for ionophoresis of L-glutamate were shifted to the right, particularly after concanavalin A treatment."( Enhancement of desensitization of quisqualate-type glutamate receptor by the dissociative anaesthetic ketamine.
Ashford, ML; Boden, P; Ramsey, RL; Usherwood, PN, 1989
)
0.28
" KA-activated currents (I(KA)) differ from QA-activated currents (I(QA)) in their dose-response characteristics, desensitization patterns, selective blockade with kynurenic acid and suppression by elevated [Ca2+]o, I(KA), but not I(QA), is significantly reduced by low levels of [Cl-]o, and the [Cl-]o-dependent shift of the reversal potential for I(KA) suggests that KA promotes a conductance decrease for Cl-."( Separation of quisqualate- and kainate-selective glutamate receptors in cultured neurons from the rat superior colliculus.
Grantyn, R; Perouansky, M, 1989
)
0.28
" At a concentration of 10 microM, CNQX reversibly antagonized responses to alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), quisqualate and kainate; it produced a parallel shift in their log dose-response curves."( 6-Cyano-7-nitroquinoxaline-2,3-dione as an excitatory amino acid antagonist in area CA1 of rat hippocampus.
Blake, JF; Brown, MW; Collingridge, GL; Yates, RG, 1989
)
0.28
" Their respective dose-response curves had a similar maximum but the slope of the curve for AMPA was consistently steeper than that for quisqualate."( The pharmacology of quisqualate and AMPA in the cerebral cortex of the rat in vitro.
Horne, AL; Simmonds, MA, 1989
)
0.28
" In this preparation, all these antagonists shifted the NMDA dose-response curve to the right in a parallel manner."( Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex.
Harrison, NL; Simmonds, MA, 1985
)
0.27
" Analysis of iontophoretic dose-response curves indicated that DL-APV was a competitive antagonist."( Action of excitatory amino acids and their antagonists on hippocampal neurons.
Hablitz, JJ, 1985
)
0.27
" This dose-response curve of L-Glu was shifted to the left in the presence of D-Asp, although the maximal amount of release was unchanged."( Effects of D-aspartate on excitatory amino acid-induced release of [3H]GABA from goldfish retina.
Cha, JH; Dowling, JE; O'Brien, DR, 1986
)
0.27
" We found that excitatory amino acid agonists evoked somatostatin release in the following order of potency: quisqualate greater than glutamate = N-methyl-D-aspartate (NMDA) greater than kainate, as calculated from the dose-response curves."( Glutamate stimulates somatostatin release from diencephalic neurons in primary culture.
Astier, H; Tapia-Arancibia, L, 1988
)
0.27
" The dose-response relationship of EAA (N-methyl-D-aspartate (NMDA), kainate, quisqualate and glutamate)-induced activation revealed qualitative and quantitative differences in their pattern of action, suggesting that these agonists act at distinct receptors."( Behavioral classification of excitatory amino acid receptors in mouse spinal cord.
Raigorodsky, G; Urca, G, 1988
)
0.27
" Dose-response analysis reveals that the AA-gated cation conductance activated by kainate requires the binding of two agonist molecules."( Properties of two classes of rat brain acidic amino acid receptors induced by distinct mRNA populations in Xenopus oocytes.
Davidson, N; Fong, TM; Lester, HA, 1988
)
0.27
" Dose-response comparisons against nifedipine in 21 patients and against isosorbide dinitrate in 14 patients demonstrate that PN 200-110 has a similar antianginal efficacy profile to both drugs."( Efficacy of a new calcium antagonist PN 200-110 (isradipine) in angina pectoris.
Allen, J; Jackson, NC; Pool, PE; Taylor, SH, 1987
)
0.27
" Dose-response curves were obtained with 4 doses of each drug in 6 animals."( Comparison of cardiodepressant and vasodilator effects of PN 200-110 (isradipine), nifedipine and diltiazem in anesthetized rabbits.
Hof, RP, 1987
)
0.27
" Dose-response curves and IC50 values were determined for these antagonists against all four agonists."( The action of quinolinate in the rat spinal cord in vitro.
Curry, K; Magnuson, DS; McLennan, H; Peet, MJ, 1987
)
0.27
"The pharmacokinetics of molsidomine were investigated in the plasma and urine of healthy male volunteers and patients with coronary heart disease after intravenous and/or oral administration of different galenic dosage forms of molsidomine."( Pharmacokinetics of molsidomine in humans.
Ostrowski, J; Resag, K, 1985
)
0.27
" The radioactivity in these organs reached a maximum approximately 1 h after dosing and then declined rapidly."( Synthesis, metabolism, and disposition of the antiinflammatory 3-[2-(4-methylphenyl)-thioethyl]-sydnone-5-14C in the rat.
Bauer, L; Bell, CL; Lu, MC; Pirl, JN, 1985
)
0.27
" When the amount of quisqualate which was simultaneously applied with glutamate was changed, the amplitudes of the maximum response of glutamate plus quisqualate did not vary much at the top of the dose-response curves."( Quisqualate action on the crayfish neuromuscular junction.
Ishida, M; Shinozaki, H, 1981
)
0.26
"In a double blind placebo-controlled trial the influence of butalamine-hydrochloride (Adrevil forte) in a daily dosage of 3 x 2 tablets on the exercise tolerance of muscles with impaired blood flow in the lower limb was evaluated."( [Conservative therapy of arterial occlusive diseases. Double-blind study on the effect of butalamine hydrochloride].
Seboldt, H, 1980
)
0.26
" 2,5-Bis(4-guanylphenyl)-1,3-oxazole and -1,3,4-thiadiazole showed good activity, whithout acute toxicity, against Trypanosoma rhodesiense in mice, producing cures at a 3 mg/kg dosage level."( Synthesis and antitrypanosomal activity of some bis(4-guanylphenyl) five- and six-membered ring heterocycles.
Boykin, DW; Das, BP; Wallace, RA, 1980
)
0.26
" Both BTI 2286E and BTI 2571E were administered as single graded po or ip dose, and their dose-response profiles were characterized."( Pharmacokinetics and amoebicidal activity of (+-)-(E)-3-(4- methylsulphinylstyryl)-1,2,4-oxadiazole (BTI 2286E) and its sulphone metabolite (BTI 2571E) in the golden hamster, Mesocricetus auratus.
Bhopale, KK; Kaul, CL; Kelkar, MG; Pargal, A; Phaltankar, PG, 1993
)
0.29
"2 mumol/kg), GR-127,935 right-shifted the dose-response curve of sumatriptan."( The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater.
Cutrer, FM; Moskowitz, MA; Waeber, C; Yu, XJ, 1997
)
0.3
" It is also devoid of the cardiovascular and behaviour side-effects of theophylline and of effects on diuresis at dosage well above the antitussive dose."( Experimental studies on the antitussive properties of the new xanthine derivative 1H-purine-2,6-dione, 3,7-dihydro-3-methyl-7[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]. 2nd communication: investigations on theophylline-like activities.
Arányi, P; Boér, K; Boronkay, E; Gyürky, J; Kapui, Z; Korbonits, D; Lacheretz, F; Mikus, EG; Pascal, M; Révész, J, 1997
)
0.3
"0 mg/kg) in combination with m-CPP produced a slight leftward shift of the dose-response curve of m-CPP."( Meta-chlorophenylpiperazine induced changes in locomotor activity are mediated by 5-HT1 as well as 5-HT2C receptors in mice.
Gleason, SD; Shannon, HE, 1998
)
0.3
" In thoracic aortic rings from CH rats, cumulative dose-response curves to phenylephrine (PE) in the presence of the nitric oxide (NO) synthase inhibitor Nomega-nitro-L-arginine (L-NNA) and the HO inhibitor zinc protoporphyrin 9 (ZnPPIX) elicited increased contractility compared with CH rings treated with only L-NNA."( Role of endothelial carbon monoxide in attenuated vasoreactivity following chronic hypoxia.
Caudill, TK; Kanagy, NL; Resta, TC; Walker, BR, 1998
)
0.3
" Drugs that produced a significant decrease in myoclonus compared with the control were studied in a dose-response study with six doses across a range from the original dose studied to 10% of that dose."( Animal model of posthypoxic myoclonus: effects of serotonergic antagonists.
Carvey, PM; Goetz, CG; Leurgans, S; Ling, ZD; Pappert, EJ; Raman, R; Vu, TQ, 1999
)
0.3
" Dose-response studies showed that all doses of methiothepin mesylate and the three highest doses of mesulergine hydrochloride inhibited myoclonus effectively."( Animal model of posthypoxic myoclonus: effects of serotonergic antagonists.
Carvey, PM; Goetz, CG; Leurgans, S; Ling, ZD; Pappert, EJ; Raman, R; Vu, TQ, 1999
)
0.3
" Treatment with pleconaril increased the survival rate in all three models for both prophylactic and therapeutic dosing regimens."( Activity of pleconaril against enteroviruses.
Groarke, JM; Pevear, DC; Seipel, ME; Tull, TM, 1999
)
0.3
" Dose-response curves were determined with N(G)-nitro-L-arginine (L-NNA) a competitive inhibitor of nitric oxide (NO) synthase; 1H-¿1,2,4ŏxadiazolol¿4, 3aquinoxalin-1-one (ODQ), an inhibitor of soluble guanylate cyclase; and oxyhemoglobin, a scavenger of nitric oxide."( Characterization of the off response to electrical field stimulation in gallbladder smooth muscle.
Conklin, JL; Cullen, JJ; Hinkhouse, MM, 2000
)
0.31
" At high (>300 mmHg) vs low (<55 mmHg) oxygen tension the dose-response curves to NO- and SNP-induced relaxations were biphasic and shifted leftward."( Nitric oxide and sodium nitroprusside-induced relaxation of the human umbilical artery.
Lovren, F; Triggle, C, 2000
)
0.31
" Panadiplon pretreatment resulted in leftward shifts in the pentobarbital dose-response function but predominantly rightward shifts of the triazolam dose-response function."( Discriminative stimulus effects of panadiplon (U-78875), a partial agonist at the benzodiazepine site, in pentobarbital-trained rhesus monkeys.
Rowlett, JK; Woolverton, WL, 2001
)
0.31
" ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one), a potent and selective inhibitor of soluble guanylyl cyclase (sGC), did not significantly affect relaxant actions of ONOO-, but ODQ markedly attenuated SIN-1-elicited relaxation with a rightward shift in the dose-response curve and an unaltered maximal response."( Comparative vasodilation of peroxynitrite and 3-morpholinosydnonimine.
Trakranrungsie, N; Will, JA, 2001
)
0.31
" The infected subjects from the corresponding active and placebo groups (three-times daily dosing regimens) were combined for analysis."( Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials.
Blatter, MM; Coats, T; Hassman, HA; Hayden, FG; Kim, K; Liu, S; Zhang, B, 2002
)
0.31
" Heterocyclic acid surrogate, oxadiazolidinone 3, demonstrated an improved pharmacokinetic property when dosed intravenously."( Influence of acid surrogates toward potency of VLA-4 antagonist.
Alves, K; Cramer, M; Gardner, MF; James, J; Lim, J; Lingham, RB; Mumford, RA; Munoz, B; Venkatraman, S, 2005
)
0.33
" Long-term dosing shifted the early/late medullary thymocyte ratio with an expansion of the late medullary compartment, as mature CD69(-) thymocytes were retained within the thymus."( CD69 down-modulation and inhibition of thymic egress by short- and long-term selective chemical agonism of sphingosine 1-phosphate receptors.
Alfonso, C; McHeyzer-Williams, MG; Rosen, H, 2006
)
0.33
" FTY-720 significantly decreased plasma creatinine in a dose-response manner with a maximal reduction of approximately 73 and approximately 69% with doses of 240 and 48 microg/kg, respectively."( Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney.
Awad, AS; Foss, FW; Huang, L; Li, L; Lynch, KR; Macdonald, TL; Okusa, MD; Ye, H, 2006
)
0.33
" Blood samples were collected during each day of midazolam dosing to determine plasma midazolam concentrations."( Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam.
Bertino, JS; Liu, S; Ma, JD; Nafziger, AN; Rhodes, G, 2006
)
0.33
" In dose-response measures, NO increased the current stimulated by cAMP injection without altering either apparent cAMP binding affinity or cooperativity of current activation."( Nitric oxide potentiates cAMP-gated cation current in feeding neurons of Pleurobranchaea californica independent of cAMP and cGMP signaling pathways.
Gillette, R; Hatcher, NG; Moroz, LL; Sudlow, LC, 2006
)
0.33
" Dose-response curves (10(-9) to 10(-6) M) to 5,6-EET, 8,9-EET, 11,12-EET, 14,15-EET, and ACh (10(-9) to 10(-4) M) were evaluated in preconstricted (10(-6) mol/l phenylephrine) mesenteric arteries (<350 microm diameter) in the presence or absence of 1) the cyclooxygenase inhibitor indomethacin (2."( Rat mesenteric arterial dilator response to 11,12-epoxyeicosatrienoic acid is mediated by activating heme oxygenase.
Abraham, NG; Bolognesi, M; Di Pascoli, M; Gatta, A; McGiff, JC; Sacerdoti, D; Schwartzman, ML, 2006
)
0.33
" No drug accumulation with repeated dosing was apparent."( Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers.
Almstead, NG; Elfring, GL; Hirawat, S; Hwang, S; Ju, W; Leonard, EM; Miller, LL; Northcutt, VJ; Paushkin, S; Peltz, SW; Welch, EM, 2007
)
0.34
" Selected compounds showed significant reduction of Abeta levels upon oral dosing in a transgenic murine model of Alzheimer's disease."( Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.
Chu, I; Clader, JW; Del Vecchio, RA; Favreau, L; Greenlee, WJ; Hyde, LA; McBriar, MD; Nomeir, AA; Parker, EM; Pissarnitski, DA; Song, L; Zhang, L; Zhao, Z, 2008
)
0.35
" Immunohistochemical analysis of tumor xenografts after repeat dosing with GSK690693 showed reductions in phosphorylated Akt substrates in vivo."( Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.
Choudhry, AE; Copeland, RA; Duckett, DR; Eberwein, DJ; Geske, RS; Gilmer, TM; Heerding, DA; Huang, PS; Kahana, JA; Kleymenova, EV; Knick, VB; Kumar, R; Lai, Z; Lansing, TJ; Leber, JD; McConnell, RT; Minthorn, EA; Rhodes, N; Robell, K; Strum, SL; Wood, ER; Zhang, SY, 2008
)
0.35
" Several of the published studies in cystic fibrosis have reported improvements in cystic fibrosis transmembrane conductance regulator (CFTR) biomarkers during short-term evaluation, including topical and systemic aminoglycoside treatment, and oral dosing with PTC124."( Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development.
Clancy, JP; Rowe, SM, 2009
)
0.35
" NOX-1 also significantly antagonized cumulative dose-response effect of norepinephrine, phenylephrine, KCl or calcium with reduction in submaximal contractions."( Vasorelaxant effect in rat aortic rings through calcium channel blockage: a preliminary in vitro assessment of a 1,3,4-oxadiazole derivative.
Bankar, GR; Chamallamudi, MR; Nampurath, GK; Nandakumar, K; Nayak, PG; Thakur, A, 2009
)
0.35
" In each case, the dose-response curve for N(2)O was progressively shifted to the right by increasing the dose of each pretreatment drug."( Involvement of a NO-cyclic GMP-PKG signaling pathway in nitrous oxide-induced antinociception in mice.
Chung, E; Ohgami, Y; Quock, LP; Quock, RM; Zhang, Y, 2011
)
0.37
" Aortic wall PAI-1 was decreased by each of the 3 dosage regimens of AZL-M (0."( The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques.
French, CJ; Sobel, BE; Zaman, AK, 2011
)
0.37
") induced a 6-fold leftward shift of the dose-response of ABT-594 (ED(50)=26 vs."( Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.
Baker, S; Brown, J; Chandran, P; Chin, CL; Decker, MW; Fox, GB; Gauvin, D; Gomez, E; Gopalakrishnan, M; Honore, P; Jacobson, PB; Komater, V; Lee, CH; Lewis, LG; Mikusa, J; Pai, M; Rustay, NR; Salyers, A; Simler, G; Tovcimak, A; Zhong, C; Zhu, CZ, 2011
)
0.37
"To study efficacy and safety of a new dose and dosage form of proxodolol--a beta-adrenoblocker with alpha1-adrenoblocking activity--in patients with moderate arterial hypertension (AH)."( [Efficacy and safety of the first made in Russia αβ long-acting adrenoblocker proxodolol in patients with arterial hypertension of the second degree].
Beliaeva, SA, 2011
)
0.37
" Finally, AZD9668 prevented airspace enlargement and small airway wall remodeling in guinea pigs in response to chronic tobacco smoke exposure whether dosed therapeutically or prophylactically."( AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase.
Churg, A; Ekholm, K; Falk-Håkansson, H; Gränse, M; Jungar, C; Kozma, V; Lal, H; Lindahl, M; Ottosson, T; Sanfridson, A; Stevens, T; Wright, JL, 2011
)
0.37
" S1P(1) agonism alone reduced pathological features as did fingolimod (maximally lymphopenic throughout), despite full reversal of lymphopenia within each dosing interval."( S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis.
Cahalan, SM; Cameron, MD; Gonzalez-Cabrera, PJ; Kago, T; Leaf, NB; Nguyen, N; Rosen, H; Sarkisyan, G, 2012
)
0.38
" With once-daily dosing and a favorable side-effect profile, azilsartan is an attractive option for the treatment of hypertension."( Azilsartan medoxomil: a new Angiotensin receptor blocker.
Cheng, JW; Zaiken, K, 2011
)
0.37
"This was a multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study in 8 healthy young men (age, 18-45 years) per dosing panel."( Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.
Albright, CF; Berman, RM; Castaneda, L; Croop, R; Dockens, RC; Gu, H; Huang, SP; Li, H; Slemmon, R; Smith, C; Sverdlov, O; Tong, G; Wang, JS; Wong, O, 2012
)
0.38
" Furthermore, the method was successfully applied to the analysis of hair specimens from rats that were continuously dosed with diphenyl(pyrrolidin-2-yl)methanol (D2PM)."( Rapid enantiomeric separation and simultaneous determination of phenethylamines by ultra high performance liquid chromatography with fluorescence and mass spectrometric detection: application to the analysis of illicit drugs distributed in the Japanese ma
Goda, Y; Higashi, T; Hirashima, H; Inagaki, S; Kikura-Hanajiri, R; Min, JZ; Taniguchi, S; Toyo'oka, T, 2012
)
0.38
" A total of 156 HSV strains were isolated prior to the dosing of patients, and no preexisting variants with less susceptibility to ASP2151 or acyclovir (ACV) were detected."( Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor.
Chono, K; Katsumata, K; Kontani, T; Suzuki, H; Takakura, S; Weinberg, A, 2012
)
0.38
" Ataluren requires 3 times a day dosing and is currently in a Phase 3 placebo-controlled study."( Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit, RS,
)
0.13
" In addition, a dose-response study was performed with IQG-607 at 5, 10, 25, 50, 100, 200 and 250 mg/kg."( Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infection.
Basso, LA; Calixto, JB; Campos, MM; de França Lopes, LG; Dos Santos Junior, A; Dos Santos, AJ; Rodrigues-Junior, VS; Santos, DS; Schneider, CZ; Sousa, EH; Souto, AA, 2012
)
0.38
" At the maximum approved dosage of 80 mg once daily, azilsartan medoxomil was significantly more effective than maximum dosages of olmesartan medoxomil (40 mg once daily) or valsartan (320 mg once daily), based on primary endpoint assessments."( Azilsartan medoxomil: a review of its use in hypertension.
Perry, CM, 2012
)
0.38
"Avagacestat dosed at 25 and 50 mg daily was relatively well tolerated and had low discontinuation rates."( Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
Albright, C; Andreasen, N; Andreasson, U; Berman, RM; Blennow, K; Brody, M; Colby, S; Coric, V; Dockens, R; Feldman, HH; Pachai, C; Pilcher, G; Portelius, E; Richter, RW; Rollin, L; Salloway, S; Shiovitz, T; Soares, H; Soininen, H; Thein, S; van Dyck, CH, 2012
)
0.38
" Nonsense read-through drugs are a potential form of treatment for PKU, although the high dosage of aminoglycosides used is not appropriate in a clinical setting."( In vitro read-through of phenylalanine hydroxylase (PAH) nonsense mutations using aminoglycosides: a potential therapy for phenylketonuria.
Christodoulou, J; Ho, G; Reichardt, J, 2013
)
0.39
" Exposure of MIN6 and GLUTag cells to MW1219 enhanced glucose-stimulated insulin secretion and GLP-1 release; once-daily oral dosing of MW1219 for 6 weeks in diabetic db/db mice reduced hemoglobin A1c (HbA1c) and improved plasma glucose, insulin and GLP-1 levels; it also increased glucose tolerance."( High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice.
Boutin, J; Feng, Y; He, M; Li, T; Nosjean, O; Renard, P; Wang, J; Wang, MW; Yang, D; Zhang, M; Zhao, J, 2013
)
0.39
"1 nM, pMCM2 IC50=32 nM) that demonstrated robust lowering of pMCM2 in a mouse pharmacodynamic (PD) model when dosed orally."( The optimization of aminooxadiazoles as orally active inhibitors of Cdc7.
Allen, JG; Bailis, JM; Bourbeau, MP; Bush, T; Escobar, S; Fotsch, C; Frohn, M; Harrington, PE; Heller, S; Hickman, D; Hsieh, F; Orf, JN; Pickrell, AJ; Reichelt, A; Rong, M; San Miguel, T; Sham, K; Siegmund, AC; Tan, H; Zalameda, L, 2013
)
0.69
" Prolonged dosing with compound 26 resulted in impaired glucose tolerance in diet-induced obese (DIO) C57BL6 mice, an unexpected finding."( Piperazine oxadiazole inhibitors of acetyl-CoA carboxylase.
Allen, JG; Bartberger, MD; Bourbeau, MP; Busby, J; Fielden, M; Fotsch, C; Graham, M; Gu, W; Kim, KW; Komorowski, R; Meyer, J; Salyers, K; Shu, H; Siegmund, A; Véniant, MM; Wang, M; Xu, Y, 2013
)
0.39
" The first cohort (n = 6) received ataluren three times per day at morning, midday, and evening doses of 4, 4, and 8 mg/kg; the second cohort (n = 20) was dosed at 10, 10, 20 mg/kg; and the third cohort (n = 12) was dosed at 20, 20, 40 mg/kg."( Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy.
Barth, J; Bönnemann, C; Elfring, G; Finkel, RS; Flanigan, KM; Northcutt, VJ; Peltz, SW; Reha, A; Sampson, J; Sweeney, HL; Wong, B, 2013
)
0.39
" Here, we used a mouse model of aniridia to test the hypothesis that manipulation of Pax6 dosage through a mutation-independent nonsense mutation suppression strategy would limit progressive, postnatal damage in the eye."( Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects.
Gregory-Evans, CY; Gregory-Evans, K; Metcalfe, AL; Wang, X; Wasan, KM; Zhao, J, 2014
)
0.4
" Sitagliptin increased active GLP-1, but caused a profound suppression of total PYY, GLP-1, and GIP when dosed alone or with GSK263."( Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
Apseloff, G; Atiee, G; Bush, MA; Collins, DA; Corsino, L; Feldman, PL; Gillmor, D; McMullen, SL; Morrow, L; Nunez, DJ, 2014
)
0.4
" To investigate the role of S1P in the development of microvascular permeability and peritubular capillary hypoperfusion in the kidney during CLP-induced AKI, we used a pharmacologic approach and a clinically relevant delayed dosing paradigm."( Pharmacologic targeting of sphingosine-1-phosphate receptor 1 improves the renal microcirculation during sepsis in the mouse.
Gokden, N; Mayeux, PR; Patil, NK; Sims, CR; Wang, Z, 2015
)
0.42
"Developing new antiretroviral therapies for HIV-1 infection with potential for less frequent dosing represents an important goal within drug discovery."( Discovery of MK-8970: an acetal carbonate prodrug of raltegravir with enhanced colonic absorption.
Balsells, J; Bennet, A; Bennett, DJ; Ceglia, SS; Chessen, G; Clas, SD; Coleman, PJ; Dang, Q; de Lera Ruiz, M; Di Marco, CN; Grobler, J; Hafey, M; Higgins, J; John, C; Kim, SH; Li, J; Manser, K; Nissley, B; Nofsinger, R; Sanchez, RI; Sanders, JM; Smith, R; Templeton, A; Wai, JS; Walji, AM; Wang, J; Wu, Y, 2015
)
0.42
"74μM (18μg/mL) when dosed at 10, 30, 100 and 200mg/kg po in mice."( The discovery and optimization of aminooxadiazoles as potent Pim kinase inhibitors.
Andrews, KL; Cee, V; Chavez, F; Guerrero, N; Herberich, B; Jackson, C; Lanman, BA; Laszlo, J; Lee, MR; Lipford, JR; Mohr, C; Nguyen, Y; Nixey, T; Pettus, LH; Reed, AB; Reid, DL; Sastri, C; Tasker, AS; Wang, HL; Wang, P; Winston, J; Wu, B; Wurz, RP; Xu, Y; Zhou, Y, 2015
)
0.69
" The simulations suggest that 25-50-kg subjects require half the adult dose (10-40 mg), whereas 50-100-kg subjects can use the same dosing as adults."( Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults.
Dudkowski, C; Juhasz, A; Tsai, M; Webb, NJ; Wells, T; Zhao, Z, 2016
)
0.43
"This dosing strategy should be safe in pediatric patients, as AZL exposure would not exceed that seen in adults with the highest approved AZL-M dose (80 mg)."( Single-dose pharmacokinetics and safety of azilsartan medoxomil in children and adolescents with hypertension as compared to healthy adults.
Dudkowski, C; Juhasz, A; Tsai, M; Webb, NJ; Wells, T; Zhao, Z, 2016
)
0.43
"The addition of opicapone 50 mg to levodopa treatment in patients with Parkinson's disease and end-of-dose motor fluctuations could enable a simplified drug regimen that allows physicians to individually tailor the existing levodopa daily regimen, by potentially reducing the total daily levodopa dose, increasing the dosing interval, and ultimately reducing the number of intakes, thereby maximising its benefit."( Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira, JJ; Lees, A; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P, 2016
)
0.43
"The meaningful reductions in ACTH and 17OHP following NBI-77860 dosing in 21OHD patients demonstrate target engagement and proof of principle in this disorder."( Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency.
Auchus, RJ; Farber, RH; Grigoriadis, DE; Luo, R; Madrigal, D; Muth, T; O'Brien, CF; Ramm, CA; Spencer-Segal, JL; Turcu, AF, 2016
)
0.43
" Consistent with this, AZD8835 demonstrated antitumor efficacy in corresponding breast cancer xenograft models when dosed continuously."( Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.
Avivar-Valderas, A; Cosulich, SC; Cruzalegui, F; Cumberbatch, M; Delpuech, O; Dudley, P; Ellston, R; Green, S; Hancox, UJ; Hanson, L; Hudson, K; Jones, A; McEwen, R; Morentin Gutierrez, P; Nikolaou, M; Polanska, UM; Trigwell, C; Ward, L, 2016
)
0.43
" However, there was a reduction in the extent of bradycardia following dosing in the fed state."( Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers.
Gray, F; Henderson, A; Hicks, K; Oliver, J; Thompson, P; Xu, J; Yang, J, 2014
)
0.4
"This phase 3 international, multicenter outpatient study evaluated a 25- and a 50-mg/d dosage of opicapone in a randomized, double-blind, 14- to 15-week, placebo-controlled clinical trial, followed by a 1-year open-label phase during which all patients received active treatment with opicapone."( Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Ferreira, J; Lees, AJ; McCrory, M; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P, 2017
)
0.46
"8] years) were randomized to a 25-mg/d (n = 129) or a 50-mg/d (n = 154) dosage of opicapone or to placebo (n = 144)."( Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
Ferreira, J; Lees, AJ; McCrory, M; Poewe, W; Rascol, O; Rocha, JF; Soares-da-Silva, P, 2017
)
0.46
" The dosage of olmesartan and azilsartan increased significantly and slightly for 16 weeks (OL group: 20."( Practical efficacy of olmesartan versus azilsartan in patients with hypertension: a multicenter randomized-controlled trial (MUSCAT-4 study).
Hanayama, Y; Kakio, Y; Okuyama, Y; Takeuchi, H; Uchida, HA; Umebayashi, R; Wada, J, 2017
)
0.46
"Determination of the effectiveness and safety of different dosing regimens during the day (in the morning or at bedtime) combination therapy including azilsartan medoxomil in patients with essential hypertension and metabolic syndrome (MS)."( [Hronotherapy Aspects of Efficiency Azilsartan Medoxomil in Combination Therapy in Patients With Hypertension and Metabolic Syndrome].
Fendrikova, AV; Sirotenko, DV; Skibitskiy, AV; Skibitskiy, VV, 2016
)
0.43
"When combined with essential hypertension and MS azilsartana use of combination drug therapy provided achievement of the target values of blood pressure in the majority of patients, a significant improvement in the main indicators of ABPM, CAP, and the rigidity of the vascular wall, as well as the normalization of daily profile of blood pressure in the majority of patients, regardless of dosing regimen during the day."( [Hronotherapy Aspects of Efficiency Azilsartan Medoxomil in Combination Therapy in Patients With Hypertension and Metabolic Syndrome].
Fendrikova, AV; Sirotenko, DV; Skibitskiy, AV; Skibitskiy, VV, 2016
)
0.43
" Opicapone was quickly absorbed (time to reach the maximum plasma concentration≤2h) in both dosage regimens and the extent of systemic exposure to opicapone increased approximately in a dose-proportional manner after single-dosing within the studied dose range (30-90mg/kg)."( Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat.
Alves, G; Falcão, A; Fortuna, A; Gonçalves, D; Soares-da-Silva, P, 2017
)
0.46
" In the renal impairment study, the area under the amenamevir concentration versus time curve from the time of dosing up to the time of the last sample with extrapolation to infinity of the terminal phase was increased by 78."( The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.
Katashima, M; Kato, K; Keirns, JJ; Kowalski, D; Kusawake, T; Lasseter, KC; Lewand, M; Marbury, TC; Preston, RA; Takada, A, 2017
)
0.46
"The findings of the hepatic impairment study indicate that no dosing adjustment is required in patients with moderate hepatic impairment."( The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.
Katashima, M; Kato, K; Keirns, JJ; Kowalski, D; Kusawake, T; Lasseter, KC; Lewand, M; Marbury, TC; Preston, RA; Takada, A, 2017
)
0.46
"Single dose high-throughput screening (HTS) followed by dose-response evaluations is a common strategy for the identification of initial hits for further development."( A multifaceted approach to identify non-specific enzyme inhibition: Application to Mycobacterium tuberculosis shikimate kinase.
Alturki, MS; Calderón, AI; Fuanta, NR; Goodwin, DC; Hobrath, JV; Jarrard, MA; Rants'o, TA, 2018
)
0.48
" AZL-M/CLD showed greater systolic BP reductions after initial dosing (P = ."( Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.
Bakris, GL; Hisada, M; Juhasz, A; Kupfer, S; Lloyd, E; Oparil, S; Zhao, L, 2018
)
0.48
" The NZBWF1 mouse model was used in therapeutic dosing mode to assess the potential benefit of ozanimod and RP-101075 in an established animal model of systemic lupus erythematosus."( Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.
Clemons, B; Opiteck, GJ; Peach, R; Scott, FL; Steinberg, MW; Stokes, ME; Taylor Meadows, KR, 2018
)
0.48
" Importantly, 5a can be prepared as a pharmaceutically acceptable salt and is observed in the brain 12 h after oral administration, suggesting potential for daily dosing and excellent metabolic stability."( Furoxans (Oxadiazole-4 N-oxides) with Attenuated Reactivity are Neuroprotective, Cross the Blood Brain Barrier, and Improve Passive Avoidance Memory.
Alhadidi, Q; Ducharme, M; Hagood, K; Horton, A; Kostrevski, A; Langenderfer, B; Nash, K; Novak, A; Post, M; Raghavan, A; Royster, K; Schiefer, IT; Shah, ZA; Tackie-Yarboi, E; Tulsulkar, J; Wamer, N, 2018
)
0.48
" Several factors hamper the use of current available catechol-O-methyl transferase inhibitors, that is, the moderate efficacy and multiple dosing for entacapone and the risk of liver toxicity with tolcapone."( Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
Fabbri, M; Ferreira, JJ; Lees, A; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E, 2018
)
0.48
"Azilsartan Medoxomil (AZL) angiotensin II receptor blocker and chlorthalidone (CLT) were determined by ultraperformance liquid chromatography (UPLC) method in their combined dosage form, they were both subjected to forced degradation studies under extensive stress conditions."( Stability-Indicating RP-UPLC Method for Simultaneous Determination of Azilsartan Medoxomil and Chlorthalidone in Tablets in the Presence of Its Degradation Products.
Hussein, LA; Ibrahim, MA; Magdy, NN, 2019
)
0.51
"Amorphous spray-dried dispersions (SDDs) are a key enabling technology for oral solid dosage formulations, used to improve dissolution behaviour and clinical exposure of poorly soluble active pharmaceutical ingredients (APIs)."( Elucidating spray-dried dispersion dissolution mechanisms with focused beam reflectance measurement: contribution of polymer chemistry and particle properties to performance.
Ferreira, AP; Nicholls, D; Nicholson, S; Rawlinson-Malone, CF, 2019
)
0.51
"Gln2598Stop), who started the treatment with Ataluren at a dosage of 2,250 mg/die, reporting a prompt subjective improvement in muscle strength."( Therapeutic approach with Ataluren in Duchenne symptomatic carriers with nonsense mutations in dystrophin gene. Results of a 9-month follow-up in a case report.
D'Ambrosio, P; Nigro, V; Orsini, C; Politano, L, 2018
)
0.48
" During single dosing of AZL, the pharmacokinetics of AZL exhibited a linear profile between dosage and area under the concentration-time curve."( Clinical Evaluation of the Tolerability and Pharmacokinetics of Azilsartan, a Potent Angiotensin Receptor Blocker, in Healthy Chinese Subjects.
Chen, G; Chen, H; Cui, D; Ding, Y; Guo, Y; Jiao, Z; Li, C; Li, X; Liu, J; Shen, Z; Sheng, C; Wu, M; Zhang, H; Zhu, X, 2020
)
0.56
" Median effective dose was interpolated from the triplicated experiments and the dose-response curves were generated for each drug-virus combination."( A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses.
Honkimaa, A; Hyöty, H; Sioofy-Khojine, AB, 2020
)
0.56
"The objective of this Letter is to report the first (to our knowledge) in vivo proof of concept for a sulfenamide prodrug to orally deliver a poorly soluble drug containing a weakly-acidic NH-acid from a conventional solid dosage formulation."( An amide-based sulfenamide prodrug of gamma secretase inhibitor BMS-708163 delivers parent drug from an oral conventional solid dosage form in male beagle dog.
Clarke, W; Everlof, JG; Guarino, VR; Haskell, R; Lentz, KA; McDonald, I; Olson, RE; Wang, N, 2020
)
0.56
"4 h in human and dosage is 50 mg BID in the phase III clinic trial."( Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors.
Guo, W; Liu, H; Meng, LH; Song, X; Sun, P; Wang, J; Wang, Y, 2020
)
0.56
" Other studies on this drug substance include drug stability, Pharmaceutical Applications, Mechanism of Action, Pharmacodynamics, and a Dosing Information are reviewed."( Azilsartan medoxomil.
Abdelhameed, AS; Al-Kahtani, HM; Al-Majed, AA; Al-Muhsin, A; Bakheit, AHH, 2020
)
0.56
"There were no clinically relevant safety concerns when 400 mg of amenamevir was administered as a single dose to hemodialysis patients without dose adjustment and/or modification of the dosing schedule."( Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients.
Endo, T; Hashimoto, N; Seo, M; Tsuruoka, S, 2020
)
0.56
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."(
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022
)
0.72
" Plasma concentrations of OPC and its metabolites were measured at 0 to 72 and 0 to 144 hours after dosing for single dose and multiple dose, respectively."( Pharmacokinetics of Opicapone and Its Metabolites in Healthy White and Chinese Subjects.
Cong, D; Hui, A; Li, K; Liu, X; Liu, Y; Qi, W; Song, J; Tan, Y; Wang, J; Xu, C; Xue, W; Zhong, L, 2021
)
0.62
"Gln3601X in exon 76, who was early treated with Ataluren at a dosage of 40 mg/kg/die, and presented a rapid improvement in both muscle strength and cognitive and social skills."( Early treatment with Ataluren of a 2-year-old boy with nonsense mutation Duchenne dystrophy.
Bertella, M; Bitetti, I; Manna, MR; Mautone, C; Varone, A, 2021
)
0.62
" Ataluren has a bell-shaped dose-response curve and a narrow effective range."( Ataluren suppresses a premature termination codon in an MPS I-H mouse.
Du, M; Gunn, G; Keeling, KM; Siddiqui, A; Wang, D; Weetall, M; Xue, X, 2022
)
0.72
"The developed method requires less time, cost, and organic solvent for analysis of the said pharmaceutical dosage forms compared to published chromatographic methods."( Chemometric and Design of Experiments-Based Analytical Quality by Design and Green Chemistry Approaches to Multipurpose High-Pressure Liquid Chromatographic Method for Synchronous Estimation of Multiple Fixed-Dose Combinations of Azilsartan Medoxomil.
Acharya, A; Prajapati, P; Shah, S; Shahi, A, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1101236Insecticidal activity against second-instar larvae of Mythimna separata (Oriental armyworm) fed on compound-treated mealie leaves measured after 5 days2001Journal of agricultural and food chemistry, Jan, Volume: 49, Issue:1
Synthesis and quantitative structure-activity relationships of new 2,5-disubstituted-1,3,4-oxadiazoles.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,817)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901317 (22.64)18.7374
1990's695 (11.95)18.2507
2000's1302 (22.38)29.6817
2010's1892 (32.53)24.3611
2020's611 (10.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.36 (24.57)
Research Supply Index8.75 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index70.61 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials257 (4.24%)5.53%
Reviews277 (4.57%)6.00%
Case Studies38 (0.63%)4.05%
Observational9 (0.15%)0.25%
Other5,476 (90.41%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]